





















































Layout and printed by Optima Grafische Communicatie, Rotterdam, the Netherlands
Modeling of prostate cancer screening:
The future directions
Modellering van prostaatkankerscreening:  
toekomstige ontwikkelingen
Thesis
to obtain the degree of Doctor from the
Erasmus University Rotterdam
by command of the
rector magnificus
Prof.dr. A.L. Bredenoord
and in accordance with the decision of the Doctorate Board.
The public defence shall be held on
Thursday 7 October 2021 at 1.00 pm
by
Abraham Mekibeb Getaneh
born in Holeta, Ethiopia.
Promotor: Prof. dr. H.J. de Koning
Other members: Prof. dr. D. Rizopoulos
Prof. dr. N. Pashayan
Prof. dr. J. Barentsz
Copromotor: Dr. E.A.M. Heijnsdijk
Contents
Chapter 1 General Introduction 7
Part 1: PSA screening for prostate cancer 25
Chapter 2 The role of modeling in the policy decision making process 
on cancer screening:  example of prostate specific antigen 
screening
27
Chapter 3 Assessment of Harms, Benefits and Cost-effectiveness of 
Prostate Cancer Screening: A Micro-Simulation Study of 230 
Scenarios
39
Part 2: Magnetic resonance imaging in prostate cancer screening 69
Chapter 4 The comparative effectiveness of mpMRI and MRI-guided 
biopsy vs regular in a population-based PSA testing:  
A modeling study
71
Chapter 5 Cost-effectiveness of multiparametric magnetic resonance 
imaging and MRI-guided biopsy in a population-based 
prostate cancer screening setting using a micro-simulation 
model
89
Part 3: Decisions Tools 109
Chapter 6 A prostate cancer risk calculator that accounts for the long-
term harms and benefits  of PSA testing: A micro-simulation 
study
111
Chapter 7 General discussion 129
Summary 147
Samenvatting 155










1.1. THE PROSTATE AND PROSTATE CANCER
The prostate is a part of the male reproductive system located between the bladder 
and penis, just in front of the rectum (Figure 1). It has the size of a chestnut, and 
as a man gets older, it tends to increase in size. Its main function is production of 
fluid that makes up part of the semen. Benign abnormalities of the prostate include 
prostatic hyperplasia and prostatitis, which should be differentiated from prostate 
cancer. Prostate cancer is a disease marked by a malignant or uncontrolled prolifera-
tion of cells in the prostate.
1.2. EPIDEMIOLOGY OF PROSTATE CANCER
Prostate cancer is the second most common diagnosed malignancy and the 5th 
leading cause of cancer mortality in men across the world1,2. Out of an estimated 
1.3 million men that were diagnosed with prostate cancer in 2018 worldwide (ac-
counting for about 14% of men diagnosed with cancer), almost 76% of them were in 
more developed regions3. The worldwide burden is expected to increase to almost 
2.3 million new cases and 740,000 deaths by 20404. The disease is most common in 
Oceania, North America, Northern and Western Europe, and the lowest incidence 
rates can be found in Asia and North Africa5 (Figure 2). In Europe, registry data have 
shown that death from prostate cancer has override death from colorectal cancer, 
being the second frequent cause of cancer-related death in men behind lung cancer6.
 




1.3. DETECTION OF PROSTATE CANCER
Prostate cancer can be detected with a blood test, measuring the level of prostate 
specific antigen (PSA) in the blood (in ng/mL). PSA is a protein produced by healthy 
as well as malignant cells in the prostate. An elevated PSA level in the blood may 
indicate an increased risk for prostate cancer7. However, a PSA test lacks specificity, 
since PSA can also be elevated due to other prostate abnormalities such as benign 
prostate hyperplasia (enlargement of the prostate) and prostatitis (inflammation of 
the prostate)8. A digital rectal examination (DRE) is another test used for the detec-
tion of abnormalities, such as nodules or irregularities, in the prostate. The location 
of the prostate, as indicated in Figure 1, allows for palpation with the index finger 
through the anus. The presence of abnormalities up on palpation may indicates an 
increased risk of prostate cancer9.
When the PSA or DRE test is suspicious, a prostate biopsy is indicated. This can 
be transrectal ultrasound-guided biopsy (the standard and widely used method) or 
 
Figure 2. Age standardized prostate cancer incidence and mortality by geographical area. (Ad-
opted from Taitt, 2018)2
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magnetic resonance imaging (MRI) targeted biopsy. The latter is conducted after of-
fering a multi-parametric magnetic resonance imaging (mpMRI) test for those men 
with suspicious PSA test result.
The introduction of mpMRI and targeted biopsy has improved the diagnosis of 
prostate cancer. The mpMRI can be used as a reflex test to avoid biopsy if the results 
are negative, whereas positive results can be used for targeting abnormal areas in 
the prostate during biopsy10-12. Areas on the mpMRI that are suggestive of prostate 
cancer are categorized according to the Prostate Imaging–Reporting and Data 
System (PI-RADS), on a scale from one to five13. Multiple studies reported that an 
MRI-targeted biopsy is superior to the standard Transrectal Ultrasonography Guided 
Biopsy (TRUSGB), because it reduces the detection of clinically insignificant prostate 
cancer while increasing the detection of significant prostate cancer 10,13,14. Barentsz 
etal., recommended that mpMRI should be an integral part of prostate cancer diag-
nosis and treatment 15.
Staging
The stage/extent of prostate cancer is determined or classified according to the 
Tumor, Node, and Metastasis (TNM) system16 (Table 1).
Table 1. Tumor, Node, Metastasis (TNM) stage definitions for prostate cancer.
T- Primary tumor
TX Primary tumor cannot be assessed
T0 No evidence of primary tumor
T1 Clinically unapparent tumor not palpable or visible by imaging
T1a Tumor incidental histological finding in 5% or less of tissue resected
T1b Tumor incidental histological finding in more than 5% of tissue resected
T1c Tumor identified by needle biopsy (e.g. because of elevated PSA)
T2 Tumor confined within the prostate
T2a Tumor involves one half of one lobe or less
T2b Tumor involves more than half of one lobe, but not both lobes
T2c Tumor involves both lobes
T3 Tumor extends through the prostatic capsule
T3a Extracapsular extension (unilateral or bilateral) including microscopic bladder neck 
involvement
T3b Tumor invades seminal vesicle(s)
T4 Tumor is fixed or invades adjacent structures other than seminal vesicles:




Prostate cancer is graded based on the Gleason grading/scoring system17. The score 
ranges from two to ten. A Gleason score of six and below is low-grade, seven is 
intermediate-grade, and a score of eight to ten is high-grade cancer. The Gleason 
score is very important for predicting the behavior of prostate cancer. It is used to 
determine the aggressiveness of the tumor, and helps to choose appropriate treat-
ment options.
1.4. TREATMENT
Treatment of men diagnosed with localized prostate cancer with curative intent 
includes radical prostatectomy (RP), radiation therapy (RP), and active surveillance 
(AS).
Radical prostatectomy is a curative treatment of prostate cancer that involves surgi-
cal removal of the prostate and seminal vesicles. According to the Scandinavian 
Prostate Cancer Group Study Number 4 (SPCG-4), in men with localized prostate 
cancer, RP is associated with a substantial reduction of both overall and cancer-
specific mortality (relative risk of 0.71 and 0.56 respectively) as compared to watch-
ful waiting18. The study also suggested that the mortality benefit of RP declines with 
age, where the benefit was largest in men younger than 65 years of age.
RT involves radiation of the prostate and can be given either by an external beam 
radiation source or by brachytherapy19. There are no data from a randomized con-
trolled trial that compare the treatment outcomes of RP and RT.
Table 1. Tumor, Node, Metastasis (TNM) stage definitions for prostate cancer. (continued)
N-Regional lymph nodes
NX Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis
N1 Regional lymph node metastasis
M-Distant metastasis
MX Distant metastasis cannot be assessed
M0 No distant metastasis
M1 Distant metastasis





Active surveillance is a method of closely monitoring men with low-risk prostate 
cancer rather than treating them immediately after diagnosis. It involves a series of 
PSA testing, DRE, prostate biopsies, or a combination of these to monitor progres-
sion with an intent to start curative treatment (RP or RT) for those who develop 
signifi cant disease20. AS should be differentiated from watchful waiting (WW). In 
WW, treatment is initiated when symptoms arise (no curative intent). WW is usually 
a reasonable choice in men with localized prostate cancer and a life expectancy of 
less than 10 years21.
1.5. SCREENING FOR PROSTATE CANCER
Screening is the use of tests across a population in order to identify individuals 
who have a disease but do not yet show clinical symptoms22. Likewise, a PSA test is 
used as a screening tool for detecting early prostate cancer among asymptomatic 
men7. The time by which screening advances the detection of (prostate) cancer by 
symptom is called the lead-time23 (Figure 3). Prostate cancer is characterized by slow 
development and therefore has a long lead-time24-26. Conversely, in most of the time 
A. Without prostate cancer 
Birth                                                                                                                          Other cause death 
B. With prostate cancer and without screening 
Birth          PC onset                                     Clinical detection      Death from PC
                                                                                                                                 Life years lost
                                                                                                                                 due to PC
C. With prostate cancer and with screening 
Birth          PC onset                                                                        
                              Screen detected 
                              preclinical prostate cancer                   Lead time                     Life years gained                         
                                                                                                                                due to screening   
                                                                                                                                (by averting PC death)
                                                                 Figure 3. Schematic representation of the basic principle of screening. Prostate cancer onset is 
the time tumor starts in a preclinical phase. PC= prostate cancer
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it is too advanced to be cured when detected without screening27, because in that 
case more cancers are diagnosed at stage 3 and above.
Benefits of prostate cancer screening
The aim of PSA screening is to reduce the risk of prostate cancer mortality and meta-
static disease by finding and treating prostate cancer at an early stage. The European 
Randomized study of Screening for Prostate Cancer (ERSPC)28, the Prostate, Lung, 
Colorectal and Ovarian cancer Screening trial (PLCO)29, and The Cluster Randomized 
Trial of PSA Testing for Prostate Cancer (CAP)30 were the three large randomized 
clinical trials on prostate cancer screening.
The ERSPC that included centers in seven European countries was initiated in the 
early 1990s with the aim of evaluating the effect of PSA screening on prostate cancer 
mortality31. A total of  162,243 men in the core age group (55-69 years) were random-
ized either to the control (no screening) or intervention group (screening). In most 
centers, a PSA cutoff 3.0 ng/mL was used to refer suspicious men to biopsy. The 
screening interval was four years except in the Swedish center, where the interval 
was two years. The most recent results of the trial, after 16 years follow-up, showed 
a 20% relative prostate cancer mortality reduction in the intervention arm28. The 
numbers of men needed to invite for screening and the numbers needed to diagnose 
in order to avert one prostate cancer death were 570 and 18 respectively. Unlike the 
ERSPC study, the PLCO and CAP trials didn’t show a significant mortality benefit29,30 
However, there are many differences in the design and implementation among the 
trials that could explain the discrepancy. Recently published secondary analyses 
show that the ERSPC and PLCO trials, in fact, provide compatible evidence that 
screening reduces prostate cancer mortality23,32. Whether the insignificant results 
from the CAP trial change the evidence of PSA testing was tried to address in this 
thesis by replicating the trial using a simulation model (Chapter 2).
Harms of prostate cancer screening
The benefits of PSA screening are also accompanied by some adverse effects. PSA 
testing leads to an overdiagnosis of indolent prostate cancer, which has been further 
compounded by the limitations of traditional diagnosis by transrectal ultrasound-
guided biopsy33. Overdiagnosis is defined as detection of cancer because of screening 
that would not have been clinically diagnosed during the man’s life time in the ab-
sence of screening. Treating such cancer is considered an overtreatment. The rates 
of overdiagnosis with PSA screening have been estimated to be up to 50% (based on 
trials)34. Side effects of active treatments of prostate cancer include erectile dysfunc-
tion, incontinence, and bowel problems35,36. Apart from this, a study indicated that 
15
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about 75% of men who have a prostate biopsy due to an elevated PSA level are found 
not to have prostate cancer37, and this called a false positive result. False-positive 
results from a PSA test may leads to psychological problems, and also unnecessary 
biopsy which is accompanied by pain and sometimes complications38. The false-
positive and complication rates from a biopsy are higher in older men34. All these 
harms have negative impacts on quality of life.
1.6. GUIDELINES ON PROSTATE CANCER SCREENING
Given the above harms of prostate cancer screening, in 2012 the US Preventive Ser-
vices Task Force (USPSTF) recommended against PSA screening39, which resulted in 
a reduction of the uptake of PSA test for early detection in US after the year 201240. 
However, in the same period, the incidence of advanced prostate cancer started to 
rise and the declining trend in prostate cancer mortality stopped41,42 (Figure 4). In 
the United Kingdom, 4 out of 10 prostate cancer diagnoses are currently diagnosed 
at a locally advanced or metastatic stage6.
In 2018 the USPSTF revised the 2012 recommendation by giving a C recommendation 
for screening between age 55 to 69 years, and the decision to undergo this screening 
should be an individual one43. The USPSTF gave this recommendation mainly based 
on the ERSPC and PLCO trials, and the risk of overdiagnosis was calculated by com-
paring the number of cancers diagnosed in the screening groups with the number 
diagnosed in the control groups over follow-up years. However, the estimation of 
Figure 4. Trends in age-adjusted cancer death rates by site, male, US. Adopted from an European 
policy paper on PSA screening for prostate cancer6.
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overdiagnosis over the given trial period of 11-13 years only is not enough due to the 
natural history of prostate cancer. Sufficient length of follow-up periods is essential 
to account for the effects of lead time in general44. Furthermore, in the trials all 
men with elevated PSA level were receiving systematic biopsy, and did not consider 
multiparametric magnetic resonance imaging (mpMRI). The European Association 
of Urology (EAU) on the other hand recommended that baseline PSA should be 
obtained at the age of 45–50 years to initiate an individualized risk-adapted early de-
tection strategy45. Despite the existing guidelines, prostate cancer remains the most 
common cause of cancer-related morbidity and mortality among men. Recently the 
EAU emphasized that organized population-based PSA screening programs should 
be implemented at a European level to reduce prostate cancer mortality41.
1.7. ORGANIZED POPULATION BASED SCREENING
Despite the evidence about the benefits of prostate-specific antigen (PSA) screening 
on the reduction of mortality and metastatic disease23,28,46,47, almost no country has 
yet introduced a population-based prostate cancer screening program, in contrast 
with breast, cervical, and colorectal cancers. Lithuania is the only country that has 
national PSA test program, but the biopsy referral after a positive test is insuffi-
ciently low48.  However, there is high uptake of opportunistic PSA testing in many 
countries29,49,50. This form of screening is usually less efficient and accompanied by a 
high risk of overdiagnosis51,52, mainly due to screening at high ages.
However, some important questions such as the age at which PSA screening should 
start, at what age it should stop, and at what frequency to screen remains debatable 
and need to be investigated more. Furthermore, assessing the effects of triage tests, 
like mpMRI, for reduction of the harms of prostate cancer screening (unnecessary 
biopsy, ovediagnosis, and overtreatment) in a population-based screening setting can 
have a profound impact. Cost is another important factor that policy-makers need 
to consider to implement a given strategy. However, finding the optimal screening 
strategy that can lead to a better balance between the harms and benefits would 
require comparisons of various alternative screening strategies, which is impossible 
to do in a single randomized controlled trial (RCT). Additionally, RCTs generally 
have limited follow-up time and due to this it is impossible to assess the long-term 
effects of screening such as overdiagnosis, overtreatment and life-years gained. This 
is particularly true for prostate cancer where the lead time is often long. Therefore, 
modeling can play a crucial role for bridging the gap between published evidence 
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and the information we need to develop guidelines, as seen, for example, in breast 
and colorectal cancer screening53.
1.8. MICRO-SIMULATION MODEL
Microsimulation is a modeling technique that typically uses a large sample size 
of individual units (micro units), each with a unique set of attributes, and allows 
for simulations of downstream events on the basis of predefined states and the 
transition probabilities between those states over time54. In this thesis, a MIcro-
Simulation SCreening ANalysis (MISCAN) prostate cancer model is used to assess the 
long-term effects of various prostate cancer screening strategies (scenarios), mainly 
in a population-based screening setting. The model has been described throughout 
the thesis, and further detail descriptions can also be found in previous studies55,56.
Briefly, MISCAN prostate is a semi-Markov model that simulates individual life 
histories. By simulating the life histories without and with screening, the effects of 
screening can be evaluated. The model contains four main parts: demography, natu-
ral history of the diseases, treatment, and screening parts. First, the demographic 
part simulates individual life histories, where each individual in the population 
has a date of birth and date of other cause of death. Following this, the natural 
history part simulates prostate cancer histories. Individuals may develop prostate 
cancer depending on the onset probability. Once a man develops prostate cancer, 
the cancer can progress to different preclinical states. There are 18 preclinical states 
as a combination of T-stages, Gleason scores, and metastatic stages. From these pre-
clinical states the cancer has a chance to progress to clinical disease states. Third, 
the treatment part simulates the life histories after clinical detection. The screening 
part super-impose screening test(s) on the life histories in the absence of screening. 
Therefore, screening can alter a life history for a part of screen detected men.
1.9. RESEARCH QUESTIONS AND THESIS OUTLINE
This thesis is subdivided in three parts:
Part 1: PSA screening for prostate cancer
In this first part of the thesis, we will assess the role of modeling in the policy 
decision making process for (prostate) cancer screening. Furthermore, using the 
MISCAN-prostate cancer model, we will try to find an optimal prostate cancer 
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screening strategy at a population level by comparing several screening scenarios. 
Long-term effects such as prostate cancer mortality reduction, life-years gained, 
QALYs gained, overdiagnosis, and costs were considered in the comparison.
Research question 1: Can models provide additional insights beyond the observed data 
of randomized controlled trials? (Chapter 2)
Research question 2: Can we find an optimal cost-effective prostate cancer screening 
strategy at population level? If so, what are the associated long-term harms and 
benefits? (Chapter 3)
Part 2: Magnetic resonance imaging in prostate cancer screening
The introduction of mpMRI and targeted biopsy has changed the diagnostic pathway 
for prostate cancer, and various studies proposed MRI as a means for reducing the 
harms of PSA-based prostate cancer screening. However, given the natural history of 
prostate cancer there is lack of reports on the long-term effects of MRI based screen-
ing. Therefore, in the second part of this thesis, the long-term effects of MRI based 
prostate cancer screening will be compared with regular screening in a population-
based screening setting.
Research question 3: Does the use of mpMRI as a triage test followed by an MRI-guided 
biopsy result in a better harm-benefit balance compared to regular PSA screening? 
(Chapter 4)
Research question 4: Is the MRI-based prostate cancer screening more cost-effective 
than the regular screening pathway? (Chapter 5)
Part 3: Decision tools
Although various studies have confirmed the benefits of organized PSA screening, 
almost no country has yet introduced a population-based screening program. Cur-
rent prostate cancer guidelines recommend that the decision to undergo early PSA 
testing should be shared between patients and their physicians. However, the path 
from PSA testing to treating prostate cancer includes several decision points, and 
making the right decision at each of these points is not straightforward. This has 
led to the development of various prostate cancer risk prediction tools/calculators. 
Although the existing calculators have their own strength, they also lack several 
long-term (lifetime) predictions. Therefore, in the third part of the thesis, we will 
try to develop a decision tool that can supplement other risk prediction tools and 
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improve the patient-physician decisions about a PSA test and selection of immediate 
treatment for localized prostate cancer.
Research question 5: Can we develop an online tool, with long term predictions, for 
patient-physician decision about prostate cancer screening? (Chapter 6)
This thesis concludes, in chapter 7, with summery answers to and further discussion 
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Although randomised controlled trials are the preferred basis for policy decisions on 
cancer screening, it remains difficult to assess all downstream effects of screening, 
particularly when screening options other than those in the specific trial design 
are being considered. Simulation models of the natural history of disease can play 
a role in quantifying harms and benefits of cancer screening scenarios. Recently, 
the US Preventive Services Task Force issued a C-recommendation on screening 
for prostate cancer for men aged 55–69 years, implying at least moderate certainty 
that the benefit is small. However, modelling based on data from the European 
Randomized study of Screening for Prostate Cancer, which included quality-of-life 
estimates, showed that the ratio between benefits and harms is better, and likely to 
be reasonable, for men screened between the ages of 55 and 63 years (i.e. by using 
an earlier stopping age than applied in the trial setting). This commentary article 
considers the importance of simulation modelling in the decision-making process 
for (prostate) cancer screening. The paper also explores whether the recently pub-
lished Cluster Randomized Trial of PSA Testing for Prostate Cancer, a trial of a single 
prostate specific antigen (PSA) testing intervention in the UK, changes the evidence 
for regular PSA testing for men aged 55–63  years by replicating the trial using a 
simulation model.
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INTRODUCTION
Although randomised controlled trials (RCT) are preferred as the basis for decisions 
regarding efficacy of cancer screening, it is almost impossible to directly assess long-
term effects of screening such as overdiagnosis, overtreatment or life-years gained. 
This would, for instance, require a long or even lifelong follow-up of individuals in 
both the screening and control arms of such trials. Furthermore, finding the optimal 
screening strategy for a population would require formal comparisons of different 
screening strategies, which is impossible to do in a single RCT. This complexity 
of decision making has led to the need for (simulation) modelling of the natural 
history of disease. Modelling allows the impact of various screening strategies, as 
well as the long-term effects of cancer screening, to be assessed, provided that the 
model is well calibrated and validated.
There are numerous examples of such quantifications being a valuable source for 
policy decision making. For example, the US Preventive Services Task Force (USP-
STF)1-3 used results from modelling studies by Cancer Intervention and Surveillance 
Modeling Network (CISNET) groups on lung, breast and colorectal cancer screening4-6 
to assess the optimum age at which to begin and end screening, the optimal screen-
ing interval, and the relative benefits and harms of different screening strategies. 
Similarly, the Dutch government has implemented a national program for colorec-
tal cancer screening, for which the target age range, the type of test and the cut-off 
for referral were chosen based on modelling results from several pilot projects and 
predicted capacity needs for colonoscopy.7 The BreastScreen Australia Evaluation 
Advisory Committee (EAC), in its final report8, used evidence from modelling stud-
ies9,10 on the effectiveness of breast cancer screening by age. A more recent Austra-
lian example was modelling to assess the possible benefits and cost-effectiveness of 
the renewed national cervical cancer screening program in Australia.11
PROSTATE CANCER SCREENING
The risks and benefits of prostate specific antigen (PSA) testing for prostate cancer at 
a population level have been reviewed for decades, yet no country in the world has 
found sufficient evidence to fund an organised screening program. Reviews, includ-
ing in Australia, have deemed that the harms outweigh the benefits at a population 
level, due primarily to the low specificity of the PSA test and the risks of unnecessary 
invasive treatments with significant side-effects.12 Prostate cancer is nonetheless a 
good example of how (simulation) modelling can help to answer important ques-
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tions about improved targeting of early detection interventions, such as at what age 
a man might be encouraged to have his first PSA test and especially at what age a 
man who had already agreed to be tested might stop.
Existing guidelines on prostate specific antigen screening are contradictory.13,14 For 
example, the USPSTF issued a C-recommendation on screening for prostate cancer 
for men aged 55–69 years, advising clinicians to inform men about the potential 
benefits (cancer deaths prevented, life-years gained and reduction of risk of ad-
vanced disease) and harms (overtreatment and living longer with the knowledge of a 
cancer diagnosis) of PSA screening.13 According to the USPSTF, a C-recommendation 
means there is at least moderate certainty that the benefit is small, and, therefore, 
selectively offering the test to individual patients based on professional judgement 
and patient preferences might be appropriate. Based on the 13-year follow-up of 
the European Randomized study of Screening for Prostate Cancer (ERSPC) trial, the 
USPSTF concluded that screening may prevent one to two prostate cancer deaths 
(over 13 years) per 1000 men screened, and 20–50% of men detected by screening 
may be overdiagnosed. The risk of overdiagnosis was calculated by comparing the 
number of cancers diagnosed in the screening group with the number diagnosed in 
the control group over follow-up years. However, estimating overdiagnosis over the 
given trial period only is often not enough, and, given the natural history of prostate 
cancer, longer follow-up is needed or has to be simulated.
Pashayan et al.15 concluded that the benefit of prostate cancer screening in reducing 
advanced stage disease is counterbalanced by overdiagnosis, the latter being espe-
cially more frequent at older ages (65–69 years). Pinsky et al16 concluded that the 
burden from diagnosis of indolent disease (i.e. tumours that are unlikely to become 
symptomatic during a man’s lifetime) should be reduced by not diagnosing indolent 
disease at all and by not aggressively treating diagnosed indolent disease. One of 
the possible solutions for this could be stopping screening before the age of 69. A 
model which had been developed in the Australian context did not clearly indicate 
a favourable harm–benefit ratio for prostate cancer screening.17 A comprehensive 
Australian evaluation of the evidence also found no case for a PSA-based population 
screening program.18 There may, however, be a role for modelling to help inform 
targeted approaches, beyond the guidance available through conventional evidence 
review.
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PREDICTIONS FROM A MICRO-SIMULATION ANALYSIS 
MODEL (MISCAN)
A  study using micro simulation analysis (MISCAN)  model ,calibrated on ERSPC data 
and  included quality-of-life estimates showed that the ratio between benefits and 
harms is better for men screened at 55–63 years of age than for the broader age band 
(55-69/74) screened in the trial.19 The estimated effects of screening men in different 
age groups are shown in Table 1. Model simulation is over the lifetime and thus the 
numbers of prostate cancer deaths averted (5–10 per 1000 men) are larger than the 
prostate cancer mortality reduction found in the ERSPC trial at 13 years of follow-up. 
Screening in the 55–63 years age group leads to a smaller number of prostate cancer 
deaths averted – 7 per 1000 men, compared with 10 for the 55–69 years age group. 
However, the percentage loss in quality-adjusted life years (QALYs) – the difference 
between life years gained and QALYs gained divided by the life years gained – is 
smaller in the 55–63 years age group than in the 55–69 years age group; the number 
of overdiagnoses is also much lower (23 per 1000 men, compared with 49). Although 
the ratio between harms and benefits (overdiagnosis per prostate cancer death 
averted) is better for the initial core age group (55–69 years) than for the 64–69 years 
age group (who have the highest PSA test uptake in daily clinical practice), it is 
inferior to that for the 55–63 years age group (5.4 vs 3.2, respectively). This ratio 
of 3.2 between harms and benefits is almost similar to the ratio of 3 found by the 
UK independent breast screening panel.20 The UK panel concluded that this ratio is 
acceptable for breast cancer screening.
Screening in the 55–63 years age group was found to have the best benefit and 
harm balance in this analysis. In such circumstances there may be a case for the 
USPSTF to consider a B-recommendation for PSA testing for the 55–63 or 55–59 years 





























55–63 7.0 23 3.2 62 9.0 51 7.3 17
64–69 5.0 35 7.0 39 7.8 22 4.4 43
55–69 9.8 49 5.4 83 8.4 61 6.7 27
PC = prostate cancer; QALYs = quality-adjusted life years
a Per 1000 men screened
b Percentage loss in QALYs calculated as the difference between life years gained and QALYs gained, divided by 
the life years gained.
Note: Men are followed lifetime. A prostate specific antigen threshold of 3 ng/mL and an 80% attendance to 
the screening was assumed.
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age groups, as this modelling indicates there is moderate certainty that the net 
benefit is moderate to substantial. Further work, including research that improves 
understanding of the complexities of overdiagnosis in these specific age groups, 
would add to the quality of information necessary to confidently recommend such 
a change.
ONE-TIME TESTING (CAP TRIAL) VERSUS REGULAR PSA 
TESTING (ERSPC)
The Cluster Randomized Trial of PSA Testing for Prostate Cancer (CAP), conducted 
in the UK with 408 825 men, is now the largest RCT on PSA screening.21 However, in 
the CAP trial men were offered only one PSA test, and about 36% of them accepted 
that offer. Therefore, in practice, the number of PSA tests in the CAP trial is less than 
performed in the ERSPC trial (82 299 and 140 040, respectively). The result from the 
CAP trial must therefore be interpreted bearing in mind the low acceptance rate 
(36%) and single test applied only at age 50.
We used a well-validated natural history model (MISCAN) to replicate the CAP trial, 
as best as we could, based on UK life tables, men screened by age, ERSPC incidence, 
treatment and survival rates, and assuming an 80% biopsy compliance and limited 
contamination rate of 2% per year. Analogue to PLCO (Prostate, Lung, Colorectal, 
and Ovarian) Cancer Screening Trial-experiences22, we assumed no difference in the 
natural history of prostate cancer, the performance of PSA testing and the benefit 
per screen in the UK compared with other countries in Europe or the US. Figure 1 
shows our expected prostate cancer mortality curves for the screen and control 
arms of CAP. The small expected difference between the arms (given the one test 
at low compliance) is striking. We have estimated a prostate cancer mortality rate 
ratio of 0.94 after 10 years of follow-up, not much different from the observed point 
estimate of 0.96, and well within the 95% confidence interval (0.85, 1.08).
Extending the prostate cancer mortality prediction to 15 and 20 years of follow-up 
did not alter our estimate (0.94 and 0.95 mortality rate ratio, respectively). Therefore, 
our conclusion is that although the CAP-trial of a single PSA testing intervention did 
not show statistically significant differences in prostate cancer mortality after 10 
years of follow-up, there may still be a potential mortality benefit demonstrated by 
microsimulation modelling. The low point estimate (4% statistically nonsignificant 
prostate cancer mortality reduction) observed in CAP cannot be interpreted to be 
inconsistent with the 27% benefit per screen as estimated from ERSPC, and con-
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firmed in PLCO. This implies that, even when a trial shows no mortality benefit, 
well-validated modelling can strengthen the evidence on targeted interventions for 
improved early detection.
MODEL VALIDATION
Validation is one of the main methods for achieving trust and confidence in 
healthcare models.23 Model validation methods include: face validity, verification 
(or internal validity), cross validity, external validity and predictive validity; the 
latter has been suggested to be the most desirable method.23 In several modelling 
studies, the CISNET models have been replicated by independent researchers (with 
external validation by others). For example, the MISCAN prostate model was rep-
licated by independent researchers based on the reporting of all basic parameters 
in our papers.24, 25 We have also described how the MISCAN model prediction of 
the impact of breast cancer screening fulfils predictive validity.26 In short, MISCAN 
model predictions for the impact of breast cancer screening on incidence, made 
in 1994 for a steady-state screening situation27, closely resemble the actual breast 





































Figure 1. Cumulative number of prostate cancer deaths in both arms of the CAP trial by follow-




A well-validated (simulation) model can play a crucial role in the development of 
sound cancer control policies, particularly when RCTs and other empirical studies 
are unable to give information regarding the harm–benefit ratio in the long run, and 
an optimum age or interval to screen, because of a lack of diverse trials. In this com-
mentary article, we showed how modelling is useful to quantify the ratio between 
harms and benefits, and evaluated an age category with a better harm–benefit bal-
ance for prostate cancer screening than was applied in the trials to show efficacy.
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Background: Prostate cancer screening incurs a high risk of overdiagnosis and 
overtreatment. An organised and age-targeted screening strategy may reduce the 
associated harms while retaining or enhancing the benefits.
Methods: Using a micro-simulation analysis (MISCAN) model, we assessed the 
harms, benefits and cost-effectiveness of 230 prostate-specific antigen (PSA) screen-
ing strategies in a Dutch population. Screening strategies were varied by screening 
start age (50, 51, 52, 53, 54 and 55), stop age (51-69) and intervals (1, 2, 3, 4, 8 and 
single test). Costs and effects of each screening strategy were compared with a no-
screening scenario.
Results: The most optimum strategy would be screening with 3-year intervals at 
ages 55 to 64 resulting in an incremental cost-effectiveness ratio (ICER) of €19,733 
per QALY. This strategy predicted a 27% prostate cancer mortality reduction and 28 
life years gained (LYG) per 1,000 men; 36% of screen-detected men were overdiag-
nosed. Sensitivity analyses did not substantially alter the optimal screening strategy.
Conclusions: PSA screening beyond age 64 is not cost-effective and associated with 
a higher risk of overdiagnosis. Similarly, starting screening before age 55 is not a 
favoured strategy based on our cost-effectiveness analysis.
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BACKGROUND
The incidence of prostate cancer has increased in most European countries, whereas 
prostate cancer mortality rates have declined.1,2 Most Western European countries 
have experienced a sharp rise in the incidence of prostate cancer. The observed 
trend change in the incidence and mortality of prostate cancer may be partly 
related to opportunistic prostate-specific antigen (PSA) screening and advances 
in prostate cancer treatment and diagnostic procedures.3 However, this progress 
is usually accompanied by a high risk of overdiagnosis. Various studies indicated 
that opportunistic PSA testing is less efficient and associated with a higher risk of 
overdiagnosis compared to organised screening.4,5 An organised and age-targeted 
screening strategy may reduce the associated harms while retaining or enhancing 
the benefits.
While screening for prostate cancer remains controversial, various large-scale stud-
ies have confirmed the benefit of PSA screening.6-8 Similarly a secondary analysis 
confirmed that the Prostate, Lung, Colorectal and Ovarian screening Trial (PLCO) 
and European Randomized Study of Screening for Prostate Cancer (ERSPC) provide a 
compelling and consistent evidence that screening reduces prostate cancer mortal-
ity.9 However, the question as to the age at which PSA screening should start and 
especially at what age it should stop remains debatable, mainly because of the as-
sociated harms and costs. Finding the optimal screening strategy can lead to a better 
balance between the harms and benefits for citizens. Recently, the European Asso-
ciation of Urology (EAU) recommended that a baseline PSA test should be offered to 
men aged > 50 and, men > 45 years of age having a family history of prostate cancer 
or men of African-American origin,10 whereas the US Preventive Services Task Force 
(USPSTF) recommended age 55 as the starting age and that the decision to undergo 
periodic PSA-based screening for prostate cancer should be an individual one.11
Even though evidence for the benefit of prostate cancer screening under age 55 
seems less conclusive, there are some studies that suggest a benefit of screening 
between ages 50-54.  Recently, the 18-year follow-up study from the Goteborg ran-
domised control trial, one centre of the ERSPC trial, showed a large and statistically 
significant relative prostate cancer mortality reduction (RR = 0.31) for the attendees 
in this age group.8 Similarly, two other recent studies indicated a possible benefit of 
screening for this age group.12,13. Although the overall result reported from the CAP 
(Cluster Randomized Trial of PSA Testing for Prostate Cancer) trial was insignificant, 
the highest prostate cancer mortality reduction was seen in this age group.13 The 
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insignificant result from the CAP trial may be related to the single screening offered 
and its lower acceptance rate (36%).14
Although multiple studies on prostate cancer screening have been conducted, they 
have mainly focused on screening starting at age 556,7,15,16 or did not calculate life 
years gained or quality-adjusted life years (QALYs) gained.17-19 Furthermore finding 
an optimum screening strategy requires comparison of several screening strategies. 
The present study aimed to assess the harms, benefits and an optimum cost-effec-
tiveness scenario of prostate cancer screening for men from age 50 onwards in a 




For this study we used a micro-simulation screening analysis (MISCAN) model in 
order to assess the effects of prostate cancer screening. MISCAN prostate model has 
been described extensively before6,20. In short it is a stochastic model that simulates 
individual life histories of men and the natural life histories of prostate cancer. 
Overall, the model consists of 18 preclinical detectable states combined with three 
stages (T1, T2 and T3), three Gleason scores (7, less than 7 and greater than 7) and 
two metastatic states (local-regional and distant). Each individual in the simulation 
starts with no prostate cancer. Once the individual has prostate cancer, the cancer 
can progress to different screen-detectable preclinical states. From each preclinical 
state, the cancer has a probability to progress to clinical prostate cancer (detected 
by symptoms) (Figure 1).
In the model, prostate cancer incidence and mortality are first simulated in the 
absence of screening. Prostate cancer survival in the absence of treatment (baseline 
survival) was estimated at clinical detection based on surveillance, epidemiology 
and end results data from the pre-PSA era (1983-1986). Those clinically detected men 
with local disease and having received primary treatment (radical prostatectomy 
or radiation therapy) have improved survival rates with a hazard ratio of 0.56 com-
pared to baseline survival.21 For distant cases it is assumed that treatment has no 
effect on survival. Following this, the effect of PSA screening on the natural history 
of prostate cancer is simulated. In our model, the effect of PSA screening on prostate 
cancer mortality is dependent on the lead time using a lead time-dependent cure 
probability.22
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In our model, the allocation of treatments (radical prostatectomy, radiation therapy 
and active surveillance) after the diagnosis of prostate cancer was based on age, 
stage and Gleason score as described in previous studies.3,22 It was assumed that 30% 
of men switch from active surveillance to secondary treatment during the first seven 
years.6 A Dutch life table was applied to model non-prostate cancer related death.23
Model calibration
The MISCAN prostate model was previously calibrated to ERSPC data by estimating 
parameters on duration, sensitivity and lead time dependent cure probability.15 In 
order to adapt the model to the Dutch situation and also account for younger age 
groups (50-54), the model was calibrated to prostate cancer incidence among the 
Dutch population between 1989 and 2013 by 5-year age categories from age 50 to age 
75.24 Furthermore, prostate cancer mortality predicted by the model was compared 
with observed prostate cancer mortality (among the Dutch population) over the 
same period (1989-2013) to validate our model. More information on the calibration 








































Figure 1. The MISCAN prostate cancer model. The model also contains a distinction between 
local and distant stages, but for the sake of simplicity it is not illustrated here. T= tumor stage 
and G = Gleason score
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descriptions about the four components of MISCAN prostate model (demography, 
natural history, screening and treatment) can be found at https://cisnet.flexkb.net/
mp/pub/CISNET_ModelProfile_PROSTATE_ERASMUS_001_12152009_69754.pdf.
Screening strategies
A hypothetical cohort of 10 million men in the Netherlands aged 50 in 2020 was 
sampled and simulated over a lifetime period. The reason why we used a larger 
sample size than the male population in the Netherlands is to avoid a stochastic 
noise in the model. This number was selected by increasing the sample size until 
the model outputs get stable. Screening strategies were varied by screening start 
age, stop age and screening intervals. The screening start age varied between 50 and 
55 years, and the age at which screening was stopped varied between the screening 
start ages and age 69. Screening intervals of one, two, three, four and eight years and 
once-in-a-lifetime screenings were applied.
In our study the biopsy compliance rate after a positive screen test result was as-
sumed to be 90%, with a sensitivity of 90% as observed in the ERSPC Rotterdam 
data25,26. Most ERSPC centres used a PSA cutoff value of 3 ng per milliliter as an 
indication for biopsy27, and a similar cutoff was used in our model. A screening 
attendance of 80% was assumed. For each strategy a total number of invitations, PSA 
tests done, prostate cancer detected (with and without screening), overdiagnosed 
cancer, prostate cancer death (with and without screening) and life years gained 
were predicted. The total number of biopsies was estimated by using the number 
of screen detected cancers and a mean positive predictive value of 22.7% of a biopsy 
in the screen arm of the ERSPC26 and by using the number of clinically detected 
cancers and the positive predictive value of 35.8% of a biopsy in the control arm.28
For each screening strategy, overdiagnosis was estimated as a proportion of screen-
detected prostate cancers (i.e. overdiagnosed prostate cancers divide by screen 
detected prostate cancers). The screen detected prostate cancers composed of both 
overdiagnosed prostate cancers and relevant (non overdiagnosed) prostate cancers. 
The term overdiagnosis was defined as the detection of a prostate cancer during 
screening that would not have been clinically diagnosed during the man’s lifetime 
in the absence of screening.  All the outcomes (costs and effects) were estimated over 
a lifetime period and presented per 1,000 men.
Quality of life, costs and cost effectiveness
All utility estimates, unit costs (costs of screening, biopsy, primary treatment, 
follow-up and palliative care for advanced cases) and durations in screening, biopsy 
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and treatment phases were obtained from a previous study6 (Supplementary Table 
1). Our analysis did not consider indirect costs. As described in a previous study15, 
the utility estimates for the post recovery period was obtained by combining the 
percentage of men with side effects from treatment with the utility estimates for 
those side effects. This resulted in a utility estimates of 0.95 for all men during 
the period of 1-10 years after diagnosis and after receiving radical prostatectomy 
or radiation therapy.  The utility estimates range between 0 (death) and 1 (perfect 
health) and one minus the utility estimate gives a loss in utility at each health state. 
The total loss in quality of life was estimated as follows:
where u, d and n represent the utility estimate, duration (in years, e.g. 2 months = 
1/6 year) and number of men in each health state (i) respectively. The utility esti-
mates and durations are presented in Appendix Table 1. The number of men in each 
health state was based on the model prediction. The letter “k” indicates the total 
number of health states.
QALYs gained were calculated by subtracting the total loss in quality of life from the 
net life years gained as a result of screening.
After determining the costs and effects of each screening strategy, the results were 
compared with a no-screening scenario. Both strategies that were at least as ex-
pensive as and less effective (also called “strongly dominated strategies”) than an 
alternative option and weakly dominated strategies were excluded from the cost-
effectiveness analyses. A weakly dominated strategy is defined as a strategy whose 
incremental cost-effectiveness ratio (ICER) is greater than that of a more effective 
strategy29. The remaining strategies were regarded as efficient strategies and listed 
from lowest to highest according to their ICER. The ICER was calculated as the ad-
ditional costs divided by additional QALYs gained compared with the previous less 
expensive strategy. The optimum efficient strategy was identified by comparing the 
ICERs with the willingness-to-pay (WTP) threshold per QALY. Considering a com-
monly used WTP threshold of €20,000 in a Dutch situation30, a strategy (among 
efficient strategies) with the highest ICER below this threshold was taken as the 
optimum strategy. All costs and effects were estimated at a discount rate of 3.5% 




Univariate sensitivity analyses were conducted to test the robustness of the model 
results under different assumptions. Utility estimates of different health states and 
costs of screening, diagnosis and treatment were the selected parameters for these 
analyses. The utility estimates in each health state (except for the terminal illness 
and palliative therapy) was varied using the highest (favourable) and lowest (unfa-
vourable) value (Appendix Table 1). For the terminal illness and palliative therapy, it 
is favourable for screening when the utility is low 15. All costs were varied by ±20%.
RESULTS
Calibration and validation
Our model adequately predicted the prostate cancer incidence trends in the Neth-
erlands between 1989 and 2013 (Supplementary Figure 1). Furthermore, the model 
reasonably predicted the prostate cancer mortality in the Netherlands (except for 
the 70-74 age group) over the same time period (1989-2013), and this was taken as 
validation of the model (Supplementary Figure 2).
Effects of various screening strategies
For single screening strategies (once only), screening at age 57 was found to be  most 
efficient which  resulted a 9.5 life years gain and 8.2 % prostate cancer mortality 
reduction, with 31 % of screen detected cancer overdiagnosed. Screening at 4- years 
interval from age 55 to 59 (2 tests) and at 3- years interval from age 55 to 61 (3 
tests) were found to be other efficient strategies with ICER below the optimum cost 
effectiveness cut-off (Table 1). Screening at 3-years intervals from age 55 to 64 (4 
tests) was regarded as the optimum screening strategy with an ICER closest to the 
optimum cost effectiveness cut-off. Biennial screening between 51-69 (9 tests) and 
annual screening between age 50-69 (20 tests) were accompanied by a maximum life 
years gain of 41 and 47 years per 1,000 men with a 42% and 47% life time prostate 
cancer mortality reduction respectively. However, these benefits were accompanied 
by a higher risk of overdiagnosis (39 % and 41% respectively) (Table 1) and higher 
net costs for the corresponding life years or QALYs gained (Appendix Figure 3, and 
Figure 2) compared to other strategies. The fewest life years were gained with a 
single screening at age 50. In a one-time screening strategy the highest QALYs were 
attained at age 62. For all screening intervals used in our study, screening between 
an age group 50-54 generally yielded a lower number life years gain and prostate 
cancer mortality reduction than screening in age groups 55-59 or 55-64. The harms, 
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benefits and total net costs for each screening strategy are presented in the ap-
pendix (Supplementary Table 2).
Cost effectiveness
The total costs of prostate cancer screening, diagnosis and treatment ranged from 
€739,561 at no screening to €1,583,786 with annual screening of age 50-69 per 
1,000 men (3.5% discounted). The ICER of efficient strategies, strategies on the ef-
ficient frontier, increased from €10,211 per QALY (single test at age 56) to €97,784 
per QALY (annual screening between ages 50-69). As indicated in Table 1, most of 
the efficient strategies use a screening interval of three years or less, and screening 
strategies beyond age 64 were found to be less cost-effective and associated with 
higher probabilities of overdiagnosis. Screening at 3-year intervals from ages 55 to 
64 resulted in an ICER of €19,733 per QALY, which is closest to the WTP threshold 
of €20,000 per QALY, and regarded as the optimum strategy. A 27% prostate cancer 
mortality reduction and 28 life years gained per 1,000 men were predicated in 
association with this strategy. Of all screen-detected men using this strategy, 36% 
Table 1. Harms, benefits and ICER for the efficient screening strategies. Results per 1000 men 
invited.










56 single test 1 - 6.9 29.3 10,211
57 single test 1 - 8.2 30.7 10,946
55-58 2 3 12.2 31.4 12,814
55-59 2 4 13.8 31.6 13,129
55-61 3 3 19.8 34.6 14,738
54-63 4 3 25.1 34.7 18,417
55-64 4 3 27.2 35.8 19,733
54-64 6 2 30 34.9 22,395
55-65 6 2 32.2 36 24,589
53-65 7 2 33 35.6 24,819
54-66 7 2 35 36.7 28,053
53-67 8 2 37.6 37.4 29,565
52-68 9 2 39 38.1 36,805
50-68 10 2 40.3 37.9 43,831
51-69 10 2 42 38.9 50,572
53-69 17 1 46 38 55,083
52-69 18 1 46.4 37.9 57,448
50-69 20 1 46.9 41.3 97,784
ICER= incremental cost-effectiveness ratio; PCM= prostate cancer mortality; QALY = quality adjusted life years
Chapter 3
48
were overdiagnosed. Extending the screening start age before age 55 (age 50 at the 
earliest) is less desirable (Table 1).
Sensitivity Analyses
The results from the sensitivity analyses showed that for 77% of the analyses, screen-
ing from age 55-64 with 3-year screening intervals remained an optimal strategy, 
as in the base case scenario. Varying the utility estimate of the post-recovery pe-
riod produced the greatest effect on screening stop age, screening frequency and 
incremental cost-effectiveness ratio of the optimum strategy. Using an unfavourable 
utility estimate for this parameter shifted the screening stop age of the optimum 
strategy from 64 to 61 (compared with the base case) with an ICER of €15,816. When 
the highest utility estimate was assumed for the same parameter, the screening stop 
age increased from 64 to 65, the screening frequency went from 3 to 2, QALYs gained 
rose from 24 to 33 (with a proportionate increase in the probability of overdiagnosis) 
and the ICER fell by 30%. A ±20% variation in unit costs caused the ICER of the 
optimum strategy to vary between €17,429 and €19,986 and also proportionately 
increased the effect of changing treatment costs (Table 2).
Table 2. Optimal strategies in base case and under a variety of different assumptions with their 
incremental cost effectiveness ratio.
Parameter
Optimum strategy
ICER in €Screening 
age
Interval
Base case 55-64 3 19,733
Highest utility for screening attendance 54-63 3 17,960
Lowest utility for screening attendance 55-64 3 19,416
Highest utility for diagnostic phase 55-64 3 19,371
Lowest utility for diagnostic phase 54-63 3 18,582
Highest utility for diagnosis 55-64 3 19,615
Lowest utility for diagnosis 55-64 3 19,853
Highest utility at 2 months after RP treatment 55-64 3 19,284
Lowest utility at 2 months after RP treatment 55-64 3 19,956
Highest utility at 2 months after RT treatment 55-64 3 19,516
Lowest utility at 2 months after RT treatment 55-64 3 19,771
Highest  utility at 2 months to 1 year after RP treatment 55-64 3 18,427
Lowest utility at 2 months to 1 year after RP treatment 54-63 3 19,427
Highest  utility at 2 months to 1 year after RT treatment 55-64 3 18,835
Lowest utility at 2 months to 1 year after RT treatment 54-63 3 19,494
Highest utility for AS 55-64 3 17,630
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DISCUSSION
According to the model predictions, the highest QALYs were estimated for age 62 in 
a one-time screening strategy; extending once-only screening to age 69 resulted in a 
loss in QALYs. However, extending the screening stop age yielded additional QALYs 
for the other strategies (Figure 2). This study shows that screening strategies with 
intervals of four years or shorter were more efficient than strategies with longer 
intervals. With 3-year intervals, screening between ages 55 to 64 was found to be the 
Table 2. Optimal strategies in base case and under a variety of different assumptions with their 
incremental cost effectiveness ratio. (continued)
Parameter
Optimum strategy
ICER in €Screening 
age
Interval
Lowest utility for AS 55-61 3 19,217
Highest utility for post recovery period 55-65 2 19,150
Lowest utility for post recovery period 55-61 3 15,816
Highest utility for Palliative therapy 55-61 3 17,085
Lowest utility for Palliative therapy 55-67 2 18,133
Highest utility for terminal illness 54-63 3 18,732
Lowest utility for terminal illness 55-64 3 19,380
Costs of PSA test +20% 54-63 3 18,710
Costs of PSA test -20% 55-63 2 19,472
Costs of invitation +20% 55-64 3 19,673
Costs of invitation -20% 55-64 3 19,794
Costs of biopsy +20% 54-63 3 18,664
Costs of biopsy -20% 55-64 3 19,343
Costs of RP +20% 55-64 3 19,562
Costs of RP -20% 55-64 3 17,697
Costs of RT +20% 54-63 3 19,986
Costs of RT -20% 55-64 3 17,429
Costs of AS +20% 54-63 3 18,710
Costs of AS -20% 55-64 3 19,267
Costs of staging +20% 55-64 3 19,815
Costs of staging -20% 55-64 3 19,651
Costs of follow-up +20% 55-64 3 19,783
Costs of follow-up -20% 55-64 3 19,683
Costs of advanced case  +20% 55-64 3 18,940
Costs of advanced case  -20% 54-63 3 18,989




optimum strategy. Screening beyond age 64 is less cost-effective and associated with 
a higher risk of overdiagnosis.
When comparing screening between age group 50-54 and age groups 55-59 or 55-64, 
the former resulted in lower life years and QALYs gain, and lower prostate cancer 
mortality reduction than the other two age groups. The difference in prostate cancer 
mortality benefit between these strategies may be due to the lower chance of lethal 
prostate cancer among younger age groups.
An earlier study with our model showed an increasing trend in QALYs gained only 
up to age 63. QALYs started to fall when screening stop age extended beyond this 
age.6 A possible explanation for these contradictory results could be more effective-
ness, and the lower overdiagnosis predicted in this study using the updated model 
compared to the previous one, because treating overdiagnosed cancer is the main 
cause of QALY loss. Updates in the model inputs (hazard of clinical prostate cancer 
detection and/or hazards of onset of a pre-clinical prostate tumor) in the current 
study could be the reason for the different overdiagnosis projections in the present 
and  earlier study6.  On the other hand our findings are consistent with the earlier 
study with our model that screening is less cost effective at higher age and with 
longer screening intervals. When the optimum strategy in the current study was 
compared with that in the previous study (age group 55-59 with 2-year intervals), it 
resulted in ten more life years gained at a much lower ICER and a 3% higher prob-











































Figure 2. Net costs and QALYs gained per 1,000 men. The start and end age of most optimal 
strategies given 1,2,3,4,8 and once depicted in the figure. Numbers in the legend indicate the 
screening intervals used in the model. Eff frontier = efficient frontier.
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the optimum strategy in the present study is in the same order as the 30% breast 
cancer mortality reduction reported in population-based breast cancer screening, 
which is already established in the Netherlands31.
Generally, much lower net costs of screening and higher QALYs were predicted in 
the present study (Figure 2) as compared with some previous cost-effectiveness stud-
ies.6,32,33 Factors that could explain this difference include differences in background 
risk (incidence), model assumptions and proportions of cases assigned in each treat-
ment category (radical prostatectomy, radiation therapy and active surveillance). The 
higher QALYs gained reported in our study is in line with two previous studies.15,34
Most of the results in our study are robust for the univariate sensitivity analyses. 
However, there are some parameters that produced a considerable effect on quality 
of life, which in turn altered the optimum strategy. Among these, the utility of 
post-recovery treatment is the principal one. This is due to the longer duration (nine 
years in our study) of this health state compared to the other health states. The 
use of a favourable utility estimate for this health state increased the QALYs gain 
by 8 at a lower ICER, whereas an unfavourable utility reduced the QALYs gain by 
6 compared to the base case scenario. Men undergoing prostatectomy or radiation 
therapy for localised prostate cancer experience a decline in all functional outcomes 
(urinary, sexual and bowel functions) throughout early, intermediate and long-term 
follow-up.35
To our knowledge, the present study is the first that assesses the harms, benefits 
and cost-effectiveness of prostate cancer screening using Dutch population data. In 
addition, the existing studies, none of which are specific to the Netherlands, mainly 
focused on screening starting at age 55.6,7,15,16 Therefore, the main strength of our 
study is that we were capable of considering screening before age 55, unlike several 
previous studies that mentioned this point as one of their study limitations.6,15,16 
Another strength of this study is that we evaluated 230 screening scenarios, and find 
possible to be recommend strategies when choosing for 1,2,3 or 4 tests.
Our study also had some limitations. Firstly, we did not use risk-stratified screening. 
Several studies suggest risk-based screening (for instance, screening based on PSA 
level) as one method to reduce overdiagnosis.36,37 Similarly, various studies suggest 
that a magnetic resonance imaging (MRI) guided biopsy could minimise the risk 
of overdiagnosis,38-40 but MRI is not included in our screening protocol. We did not 
consider indirect costs in our analysis. Therefore, the actual total costs of prostate 
cancer screening may turn out to be higher than estimated in our study. Finally, 
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our results are from a population based screening, and this may not be directly 
applicable in clinical practice under certain conditions. For instance a man with 
high risk of prostate cancer may benefit from screening/rescreening beyond the 
screening stop age recommended in our study. Further studies that include selection 
of men based on their risk, such as using baseline PSA, comorbidity status or using 
nomograms and/or MRI as triage test may allow to screen older age groups with a 
minimal harm, or may improve the cost-effectiveness.
In conclusion, our results indicate that PSA screening beyond age 64 is not cost-
effective and associated with a higher risk of overdiagnosis. Likewise, starting 
screening before age 55 is not a favoured strategy based on our cost-effectiveness 
analysis. Screening men with 4 tests maximum, from ages 55 to 64 with 3-year in-
tervals is considered the optimum screening strategy at a WTP threshold of €20,000.
53
Harms, benefits and cost-effectiveness of prostate cancer screening
REFERENCES
 1. Wong MCS, Goggins WB, Wang HHX, et al. Global incidence and mortality for prostate 
cancer: analysis of temporal patterns and trends in 36 countries. Eur Urol. 2016;70(5):862-
874.
 2. Taitt HE. Global trends and prostate cancer: a review of incidence, detection, and mor-
tality as influenced by race, ethnicity, and geographic location. American journal of men’s 
health. 2018;12(6):1807-1823.
 3. Etzioni R, Gulati R, Tsodikov A, et al. The prostate cancer conundrum revisited: treat-
ment changes and prostate cancer mortality declines. Cancer. 2012;118(23):5955-5963.
 4. Arnsrud RG, Holmberg E, Lilja H, Stranne J, Hugosson J. Opportunistic testing versus 
organized prostate-specific antigen screening: outcome after 18 years in the Göteborg 
randomized population-based prostate cancer screening trial. Eur Urol. 2015;68(3):354-
360.
 5. Heijnsdijk EAM, Bangma CH, Borràs JM, et al. Summary statement on screening for 
prostate cancer in Europe. Int J Cancer. 2018;142(4):741-746.
 6. Heijnsdijk EAM, De Carvalho TM, Auvinen A, et al. Cost-effectiveness of prostate cancer 
screening: a simulation study based on ERSPC data. JNCI: Journal of the National Cancer 
Institute. 2015;107(1).
 7. Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate cancer mortality: 
results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 
13 years of follow-up. The Lancet. 2014;384(9959):2027-2035.
 8. Hugosson J, Godtman RA, Carlsson SV, et al. Eighteen-year follow-up of the Göteborg 
Randomized Population-based Prostate Cancer Screening Trial: effect of sociodemo-
graphic variables on participation, prostate cancer incidence and mortality. Scandinavian 
journal of urology. 2018;52(1):27-37.
 9. Tsodikov A, Gulati R, Heijnsdijk EAM, et al. Reconciling the effects of screening on 
prostate cancer mortality in the ERSPC and PLCO trials. Ann Intern Med. 2017;167(7):449-
455.
 10. Mottet N, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 
1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2017;71(4):618-
629.
 11. Bibbins-Domingo K, Grossman DC, Curry SJ. The US Preventive Services Task Force 2017 
draft recommendation statement on screening for prostate cancer: an invitation to 
review and comment. JAMA. 2017;317(19):1949-1950.
 12. Carlsson S, Assel M, Ulmert D, et al. Screening for prostate cancer starting at age 50–54 
years. A population-based cohort study. Eur Urol. 2017;71(1):46-52.
 13. Martin RM, Donovan JL, Turner EL, et al. Effect of a low-intensity PSA-based screening 
intervention on prostate cancer mortality: the CAP randomized clinical trial. JAMA. 
2018;319(9):883-895.
 14. Getaneh AM, Heijnsdijk E, de Koning H. The role of modelling in the policy decision 
making process for cancer screening: example of prostate specific antigen screening. 
Public health research & practice. 2019;29(2).
 15. Heijnsdijk EAM, Wever EM, Auvinen A, et al. Quality-of-life effects of prostate-specific 
antigen screening. N Engl J Med. 2012;367(7):595-605.
Chapter 3
54
 16. Mühlberger N, Boskovic K, Krahn MD, et al. Benefits and harms of prostate cancer 
screening–predictions of the ONCOTYROL prostate cancer outcome and policy model. 
BMC Public Health. 2017;17(1):596.
 17. Gulati R, Gore JL, Etzioni R. Comparative effectiveness of alternative prostate-specific 
antigen–based prostate cancer screening strategies: model estimates of potential ben-
efits and harms. Ann Intern Med. 2013;158(3):145-153.
 18. Perez-Niddam K, Thoral F, Charvet-Protat S. Economic evaluation of a prostate cancer 
screening program in France: a decision model. Crit Rev Oncol Hematol. 1999;32(2):167-
173.
 19. Bermúdez-Tamayo C, Martín JJM, del Amo MdPL, Romero CP. Cost-effectiveness of per-
cent free PSA for prostate cancer detection in men with a total PSA of 4–10 ng/ml. Urol 
Int. 2007;79(4):336-344.
 20. Wever EM, Draisma G, Heijnsdijk EAM, et al. Prostate-specific antigen screening in the 
United States vs in the European Randomized Study of Screening for Prostate Cancer–
Rotterdam. J Natl Cancer Inst. 2010;102(5):352-355.
 21. Bill-Axelson A, Holmberg L, Garmo H, et al. Radical prostatectomy or watchful waiting 
in early prostate cancer. N Engl J Med. 2014;370(10):932-942.
 22. de Koning HJ, Gulati R, Moss SM, et al. The efficacy of prostate-specific antigen screening: 
Impact of key components in the ERSPC and PLCO trials. Cancer. 2018;124(6):1197-1206.
 23. van der Meulen A. Life tables and Survival analysys. Statstics, Netherlands, 2012.
 24. Prostate cancer incidence and mortality rates. Utrecht, the Netherlands: Comprehensive 
Cancer Centres (https://www.iknl.nl/nkr-cijfers).
 25. Schröder FH, van den Bergh RCN, Wolters T, et al. Eleven-year outcome of patients with 
prostate cancers diagnosed during screening after initial negative sextant biopsies. Eur 
Urol. 2010;57(2):256-266.
 26. Postma R, Schröder FH, van Leenders GJLH, et al. Cancer detection and cancer character-
istics in the European Randomized Study of Screening for Prostate Cancer (ERSPC)–Sec-
tion Rotterdam: a comparison of two rounds of screening. Eur Urol. 2007;52(1):89-97.
 27. Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a 
randomized European study. N Engl J Med. 2009;360(13):1320-1328.
 28. Otto SJ, van der Cruijsen IW, Liem MK, et al. Effective PSA contamination in the Rot-
terdam section of the European Randomized Study of Screening for Prostate Cancer. Int 
J Cancer. 2003;105(3):394-399.
 29. Cantor SB. Cost-effectiveness analysis, extended dominance, and ethics: a quantitative 
assessment. Med Decis Making. 1994;14(3):259-265.
 30. Zwaap J, Knies S, Van der Meijden C, Staal P, Van der Heiden L. Kosteneffectiviteit in de 
praktijk. Diemen: Zorginstituut Nederland. 2015.
 31. Sankatsing VDV, van Ravesteyn NT, Heijnsdijk EAM, et al. The effect of population-based 
mammography screening in Dutch municipalities on breast cancer mortality: 20 years 
of follow-up. Int J Cancer. 2017;141(4):671-677.
 32. Krahn MD, Mahoney JE, Eckman MH, Trachtenberg J, Pauker SG, Detsky AS. Screening 
for prostate cancer: a decision analytic view. JAMA. 1994;272(10):773-780.
 33. Pataky R, Gulati R, Etzioni R, et al. Is prostate cancer screening cost-effective? A mi-
crosimulation model of prostate-specific antigen-based screening for British Columbia, 
Canada. Int J Cancer. 2014;135(4):939-947.
55
Harms, benefits and cost-effectiveness of prostate cancer screening
 34. Heijnsdijk EAM, Denham D, de Koning HJ. The cost-effectiveness of prostate cancer 
detection with the use of prostate health index. Value Health. 2016;19(2):153-157.
 35. Resnick MJ, Koyama T, Fan K-H, et al. Long-term functional outcomes after treatment for 
localized prostate cancer. N Engl J Med. 2013;368(5):436-445.
 36. Loeb S, Carter HB, Catalona WJ, Moul JW, Schroder FH. Baseline prostate-specific anti-
gen testing at a young age. Eur Urol. 2012;61(1):1-7.
 37. Vickers AJ, Ulmert D, Sjoberg DD, et al. Strategy for detection of prostate cancer based 
on relation between prostate specific antigen at age 40-55 and long term risk of metas-
tasis: case-control study. BMJ. 2013;346:f2023.
 38. Schoots IG, Roobol MJ, Nieboer D, Bangma CH, Steyerberg EW, Hunink MGM. Magnetic 
resonance imaging–targeted biopsy may enhance the diagnostic accuracy of significant 
prostate cancer detection compared to standard transrectal ultrasound-guided biopsy: a 
systematic review and meta-analysis. Eur Urol. 2015;68(3):438-450.
 39. Siddiqui MM, Rais-Bahrami S, Turkbey B, et al. Comparison of MR/ultrasound fusion–
guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. JAMA. 
2015;313(4):390-397.
 40. Thompson JE, Moses D, Shnier R, et al. Multiparametric magnetic resonance imaging 
guided diagnostic biopsy detects significant prostate cancer and could reduce unneces-





Calibration and validation of the model
We used the model of Heijnsdijk et al. 2015  as a base for this study15. Model param-
eters for the natural history of prostate cancer (including transition probabilities 
and mean dwelling time), stage dependent test sensitivities and lead time dependent 
cure probability were estimated  based on the following data:
• Baseline incidence and stage distribution in 1991-1993 in the Netherlands,
• ERSPC Rotterdam trial data up to July 2004 (screen results until 2006) for both 
arms of the trial,
• Baseline incidence in Sweden in 1990, and 
• ERSPC results of Göteborg up to end of 2004.
During the calibration, the baseline incidence and incidence in control arm, detec-
tion rate in first and subsequent screens, interval cancers, clinical T-stage distribu-
tion, metastatic state and biopsy Gleason score distribution were used. In addition, 
the model was calibrated to the incidence of the Dutch population in 1992–2002.
Model updates in the current study
Because the previous model didn’t account for men younger than 55 years, we reca-
librated the model to Dutch incidence between 1989 to 2013 by 5-year age categories 
from age 50 to age 75. Parameters for the hazards of onset of a pre-clinical prostate 
tumor and clinical prostate cancer detection were calibrated to these data. During 
the calibration, for the period 1989 to 1992 we used no screening, and after 1992 
we used an estimate of increasing opportunistic PSA screening in the Netherlands, 
varying from 16% (within five years) for age group 50-55% to 41% (within five years) 
for age group 65-75% (based on CBS.nl).
Following this, we projected the incidence of prostate cancer (to check the per-
formance of the calibration) over the period from 1989 to 2013 by 5  years age 
category from age 50 to 75 (with no screening scenario from year 1989 to 1992, and 
with opportunistic screening from year 1993 to 2013 (Supplementary Figure 1). We 
also predicted the prostate cancer mortality over the same period, age categories 
and screening strategies, and compared with the observed prostate cancer mortality 
among the Dutch population to validate our model, Supplementary Figure 2. (Note: 
the model was not calibrated to the Dutch prostate cancer mortality data).
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Supplementary Figure 1. Observed and predicted prostate cancer incidence rates per 100,000 
























Supplementary Figure 2. Observed and predicted prostate cancer mortality rates per 100,000 













































Supplementary Figure 3. Net costs and life-years gained per 1000 men. The start and end age of 
most optimal strategies given 1,2,3,4,8 and once depicted in the figure. Numbers in the legend 
indicate the screening intervals used in the model.
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Supplementary Table 1. Costs, utility estimates and durations of the various phases in screen-
ing, diagnosis and treatment taken from a previous publication6 and costs were converted to 
euro. The utility estimate for the terminal illness was updated.
Intervention Unit costs 
in euros
Health states Utility estimates 
(range)
Duration






































at 2 month after 
procedure






at 2 month after 
procedure





Active surveillance 0.97 (0.85-1.00) Maximum 7 
years
One year after 
treatment 0.95 (0.93-1.00 9 years
Advanced disease






DRE = digital rectal examination; GP = general practitioner; PA = pathological research; PSA = prostate-specific 
antigen; RP = radical prostatectomy; RT= radiation therapy; AS= Active surveillance (Active surveillance con-
sists of multiple tests and corresponding costs are presented) .
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Supplementary Table 2. Harms, benefits and net costs of each screening strategies per 1000 
men‡
Screening age Interval LYs_gain# PCMR %# Overdiagnosis, as % 
of screen detected 
men
Total net costs #
in Euro
50-51 1 3.4 2.3 21.6 67,707
50-52 1 4.7 3.3 22.3 99,584
50-53 1 6.4 4.7 23.3 133,498
50-54 1 8.6 6.5 24.4 169,745
50-55 1 11.2 8.6 25.5 208,405
50-56 1 14 11.1 26.5 249,548
50-57 1 17 13.8 27.3 292,412
50-58 1 20 16.6 28.2 336,676
50-59 1 23.1 19.6 29.1 382,703
50-60 1 26.2 22.6 30 429,866
50-61 1 29.1 25.7 30.9 477,467
50-62 1 31.9 28.7 31.8 525,498
50-63 1 34.7 31.7 32.7 573,338
50-64 1 37.2 34.7 33.5 621,025
50-65 1 39.6 37.5 34.4 667,855
50-66 1 41.7 40.1 35.2 713,978
50-67 1 43.6 42.5 36.1 758,951
50-68 1 45.3 44.8 36.9 802,555
50-69 1 46.8 46.9 41.3 844,225
51-52 1 4.1 3 23 73,544
51-53 1 6 4.5 23.8 107,807
51-54 1 8.3 6.3 24.7 144,430
51-55 1 10.8 8.4 25.8 183,186
51-56 1 13.6 10.9 26.6 224,257
51-57 1 16.6 13.6 27.5 267,187
51-58 1 19.6 16.4 28.3 311,373
51-59 1 22.7 19.4 29.2 357,388
51-60 1 25.8 22.4 30.1 404,547
51-61 1 28.8 25.5 31 452,259
51-62 1 31.5 28.5 31.9 500,233
51-63 1 34.3 31.5 32.8 548,052
51-64 1 36.8 34.4 33.6 595,816
51-65 1 39.1 37.2 34.5 642,755
51-66 1 41.3 39.8 35.3 688,839
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Supplementary Table 2. Harms, benefits and net costs of each screening strategies per 1000 
men‡ (continued)
Screening age Interval LYs_gain# PCMR %# Overdiagnosis, as % 
of screen detected 
men
Total net costs #
in Euro
51-67 1 43.1 42.2 36.2 733,941
51-68 1 44.8 44.5 37 777,471
51-69 1 46.3 46.6 37.8 819,072
1
52-53 1 5.4 4.1 24.4 79,699
52-54 1 7.8 6 25.2 116,875
52-55 1 10.4 8.2 26.1 155,743
52-56 1 13.2 10.7 26.9 196,943
52-57 1 16.2 13.3 27.7 240,124
52-58 1 19.2 16.1 28.5 284,281
52-59 1 22.3 19.2 29.4 330,255
52-60 1 25.4 22.2 30.3 377,417
52-61 1 28.4 25.2 31.1 424,863
52-62 1 31.2 28.3 32 472,914
52-63 1 33.9 31.3 32.8 520,708
52-64 1 36.5 34.2 33.7 568,380
52-65 1 38.8 37 34.5 615,482
52-66 1 40.9 39.6 35.4 661,786
52-67 1 42.8 42 36.2 706,785
52-68 1 44.5 44.2 37.1  750,387
52-69 1 46 46.4 37.9 792,212
53-54 1 7.1 5.5 25.8 89,035
53-55 1 9.8 7.8 26.6 128,741
53-56 1 12.7 10.3 27.4 170,345
53-57 1 15.7 13 28.1 213,459
53-58 1 18.8 15.9 28.7 257,824
53-59 1 21.8 18.9 29.6 303,889
53-60 1 24.9 21.9 30.5 350,978
53-61 1 27.9 24.9 31.3 398,585
53-62 1 30.8 28 32.2 446,605
53-63 1 33.4 31 33 494,465
53-64 1 36 33.9 33.8 542,079
53-65 1 38.3 36.6 34.7 589,078
53-66 1 40.3 39.2 35.5 635,337
53-67 1 42.2 41.6 36.4 680,448
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Supplementary Table 2. Harms, benefits and net costs of each screening strategies per 1000 
men‡ (continued)
Screening age Interval LYs_gain# PCMR %# Overdiagnosis, as % 
of screen detected 
men
Total net costs #
in Euro
53-68 1 43.9 43.8 37.2 723,806
53-69 1 45.4 45.9 38 765,672
54-55 1 8.8 7.2 27.3 100,959
54-56 1 11.9 9.9 27.8 143,724
54-57 1 15 12.5 28.5 187,272
54-58 1 18.1 15.4 29.2 231,611
54-59 1 21.2 18.5 29.9 277,808
54-60 1 24.3 21.5 30.8 325,116
54-61 1 27.3 24.6 31.6 372,670
54-62 1 30 27.6 32.4 420,723
54-63 1 32.7 30.5 33.2 468,495
54-64 1 35.3 33.4 34.1 516,234
54-65 1 37.6 36.2 34.9 563,323
54-66 1 39.7 38.8 35.7 609,601
54-67 1 41.5 41.2 36.5 654,668
54-68 1 43.2 43.5 37.3 698,195
54-69 1 44.8 45.6 38.1 739,779
55-56 1 10.8 9 28.6 115,304
55-57 1 14.1 12 29.1 160,657
55-58 1 17.3 14.9 29.7 205,699
55-59 1 20.4 17.9 30.4 251,798
55-60 1 23.5 21 31.2 299,239
55-61 1 26.5 24.1 32 347,007
55-62 1 29.3 17.1 32.7 394,898
55-63 1 31.9 30 33.5 442,567
55-64 1 34.5 32.9 34.3 490,374
55-65 1 36.8 25.7 35.2 537,560
55-66 1 38.9 38.3 36 583,689
55-67 1 40.7 40.7 36.8 628,750
55-68 1 42.4 42.9 37.6 672,170
55-69 1 43.9 45 38.4 714,210
50-52 2 4.2 3 22.7 71,321
50-54 2 7.7 5.8 24.7 114,180
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Supplementary Table 2. Harms, benefits and net costs of each screening strategies per 1000 
men‡ (continued)
Screening age Interval LYs_gain# PCMR %# Overdiagnosis, as % 
of screen detected 
men
Total net costs #
in Euro
50-56 2 12.3 9.8 26.8 167,204
50-58 2 17.6 14.7 28.7 228,879
50-60 2 23.1 20.2 30.8 298,127
50-62 2 28.4 25.7 32.6 371,283
50-64 2 33 31.1 34.4 446,379
50-66 2 37.1 36 36.2 520,377
50-68 2 40.3 40.3 37.9 591,728
51-53 2 5.3 4 24.1 79,266
51-55 2 9.4 7.4 26.2 127,589
51-57 2 14.5 11.9 28.1 185,639
51-59 2 20 17.2 29.9 251,177
51-61 2 25.4 22.7 31.8 322,930
51-63 2 30.4 28.2 33.6 397,136
51-65 2 34.8 33.4 35.4 471,937
51-67 2 38.4 38 37.2 545,195
51-69 2 41.3 42 38.9 614,461
52-54 2 6.9 5.3 25.5 87,856
52-56 2 11.6 9.4 27.2 141,295
52-58 2 16.9 14.3 29.1 203,241
52-60 2 22.4 19.8 31 272,344
52-62 2 27.7 25.3 32.8 396,875
52-64 2 32.4 30.7 34.6 420,685
52-66 2 36.4 35.6 36.4 494,786
52-68 2 39.6 39 38.1 566,150
53-55 2 8.6 6.9 27 99,182
53-57 2 13.8 11.5 28.5 157,624
53-59 2 19.3 16.7 30.3 223,847
53-61 2 24.7 22.3 32.1 295,114
53-63 2 29.7 27.8 33.8 369,373
53-65 2 34 33 35.6 444,315
53-67 2 37.7 37.6 37.4 517,344
53-69 2 40.6 41.6 39.1 586,440
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Supplementary Table 2. Harms, benefits and net costs of each screening strategies per 1000 
men‡ (continued)
Screening age Interval LYs_gain# PCMR %# Overdiagnosis, as % 
of screen detected 
men
Total net costs #
in Euro
54-56 2 10.6 8.7 28.1 113,032
54-58 2 16 13.8 29.5 175,548
54-60 2 21.4 19.1 31.5 245,277
54-62 2 26.7 24.7 33.2 318,595
54-64 2 31.4 30 34.9 393,306
54-66 2 35.4 35 36.6 467,617
54-68 2 38.7 39.3 38.3  538,613
55-57 2 12.5 10.6 29.4 128,653
55-59 2 18.1 16 30.9 195,731
55-61 2 23.5 21.5 32.6 267,681
55-63 2 28.4 27 34.3 342,055
55-65 2 32.8 32.2 36 416,909
55-67 2 36.5 36.8 37.7 490,133
55-69 2 39.4 40.9 39.4 559,212
50-53 3 5.4 4 23.9 77,098
50-56 3 11.2 9 27.3 137,770
50-59 3 18.3 15.8 30.3 217,938
50-62 3 25.4 23.3 33.3 310,874
50-65 3 31.6 30.5 36.1 408,890
50-68 3 36.2 36.7 38.8 504,367
51-54 3 6.7 5.1 25.4 87,369
51-57 3 13.2 10.9 28.4 155,053
51-60 3 20.4 18 31.6 240,855
51-63 3 27.3 25.6 34.3 336,143
51-66 3 32.9 32.5 37.1 433,983
51-69 3 37.1 38.2 39.7 526,931
52-55 3 8.3 6.6 26.9 97,903
52-58 3 15.3 13.1 29.5 171,907
52-61 3 22.6 20.4 32.5 261,920
52-64 3 29.1 27.9 35.3 358,897
52-67 3 34.3 34.4 38.1 456,083
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Supplementary Table 2. Harms, benefits and net costs of each screening strategies per 1000 
men‡ (continued)
Screening age Interval LYs_gain# PCMR %# Overdiagnosis, as % 
of screen detected 
men
Total net costs #
in Euro
53-56 3 10.3 8.4 27.9 111,058
53-59 3 17.5 15.3 30.7 191,329
53-62 3 24.6 22.8 33.6 284,457
53-65 3 30.7 30 36.3 382,326
53-68 3 35.3 36.1 39.1  477,848
54-57 3 12.2 10.3 29.1 126,061
54-60 3 19.6 17.5 31.9 211,981
54-63 3 26.4 25.1 34.7 307,322
54-66 3 32.1 32 37.4 405,265
54-69 3 36.2 37.6 40 498,236
55-58 3 14.1 12.2 31.4 142,724
55-61 3 21.5 19.8 34.6 233,213
55-64 3 28 27.2 35.8 330,487
55-67 3 33.2 33.7 38.5 427,619
50-54 4 6.7 5.1 25.4 85,165
50-58 4 14.7 12.5 29.7 166,997
50-62 4 23.4 21.6 33.8 275,677
50-66 4 30.4 30.1 37.7 393,013
51-55 4 8.1 6.4 27 97,337
51-59 4 16.6 14.5 30.9 187,638
51-63 4 25 23.6 34.9 299,786
51-67 4 31.4 31.8 38.7 417,006
52-56 4 9.9 8.1 28 109,627
52-60 4 18.6 16.7 32.1 207,207
52-64 4 26.7 25.7 36 321,823
52-68 4 32.6 33.5 39.7 437,450
53-57 4 11.8 9.9 29.2 123,846
53-61 4 20.6 18.9 33.1 227,416
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Supplementary Table 2. Harms, benefits and net costs of each screening strategies per 1000 
men‡ (continued)
Screening age Interval LYs_gain# PCMR %# Overdiagnosis, as % 
of screen detected 
men
Total net costs #
in Euro
53-65 4 28.2 27.8 37 344,003
53-69 4 33.5 35 40.6 457,420
54-58 4 13.7 11.8 30.3 139,828
54-62 4 22.4 21 34.2 248,612
54-66 4 29.4 19.6 38 365,978
55-59 4 15.5 13.8 31.6 158,123
55-63 4 24 23 35.3 270,662
55-67 4 30.4 31.2 39.1 388,003
50-58 8 12.3 10.7 31 132,214
50-66 8 23.1 23.6 39.7 298,455
51-59 8 13.5 12.1 32.4 149,097
51-67 8 23.4 24.5 40.9 317,826
52-60 8 14.8 13.7 33.8 164,767
52-68 8 24 25.6 41.9 334,029
53-61 8 16.2 15.3 34.9 181,253
53-69 8 24.6 26.6 42.9 349,793
54-62 8 17.5 16.9 36 198,825
55-63 8 18.8 18.6 37 216,573
50 single test - 2.3 1.6 20.8 36,229
51 single test - 2.5 1.7 22.4 39,781
52 single test - 3.2 2.3 24 43,183
53 single test - 4.2 3.2 25.3 48,765
54 single test - 5.4 4.3 26.6 56,535
55 single test - 6.7 5.5 28.2 66,131
56 single test - 8.2 6.9 29.3 77,082
57 single test - 9.5 8.2 30.7 89,394
58 single test - 10.7 9.6 32 102,211
59 single test - 11.7 10.9 33.6 116,231
67
Harms, benefits and cost-effectiveness of prostate cancer screening
Supplementary Table 2. Harms, benefits and net costs of each screening strategies per 1000 
men‡ (continued)
Screening age Interval LYs_gain# PCMR %# Overdiagnosis, as % 
of screen detected 
men
Total net costs #
in Euro
60 single test - 12.5 12 35.3 130,803
61 single test - 13.2 13.1 36.7 144,401
62 single test - 13.6 14 38.3 157,753
63 single test - 13.8 14.7 39.8 169,896
64 single test - 13.8 15.2 41.4 181,158
65 single test - 13.7 15.6 43.1 191,658
66 single test - 13.3 15.7 44.7 200,704
67 single test - 12.7 15.6 46.4 208,283
68 single test - 12.1 15.4 48.1 213,560
69 single test - 11.3 15 49.8 217,594
PCM = prostate cancer mortality reduction; LYs_gain = life-years gain
‡ Life years gain and costs are 3.5% discounted
# Compared to no screening
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The benefit of prostate cancer screening is counterbalanced by the risk of over-
diagnosis and overtreatment. The use of a multi-parametric magnetic resonance 
imaging (mpMRI) test after a positive prostate-specific antigen (PSA) test followed by 
magnetic resonance imaging-guided biopsy (MRIGB) may reduce these harms. The 
aim of this study was to determine the effects of mpMRI and MRIGB vs the regular 
screening pathway in a population-based prostate cancer screening setting. A micro-
simulation model was used to predict the effects of regular PSA screening (men with 
elevated PSA followed by TRUSGB) and MRI based screening (men with elevated 
PSA followed by mpMRI and MRIGB). We predicted reduction of overdiagnosis, 
harm-benefit ratio (overdiagnosis per cancer death averted), reduction in number of 
biopsies, detection of clinically significant cancer, prostate cancer death averted, life-
years gained (LYG), and quality adjusted life years (QALYs) gained for both strategies. 
A univariate sensitivity analysis and threshold analysis were performed to assess 
uncertainty around the test sensitivity parameters used in the MRI strategy.In the 
MRI pathway, we predicted a 43% reduction in the risk of overdiagnosis, compared 
to the regular pathway. Similarly a lower harm-benefit ratio (overdiagnosis per can-
cer death averted) was predicted for this strategy compared to the regular screening 
pathway (1.0 vs 1.8 respectively). Prostate cancer mortality reduction, LY and QALYs 
gained were also slightly increased in the MRI pathway than the regular screening 
pathway. Furthermore, 30% of men with a positive PSA test could avoid a biopsy as 
compared to the regular screening pathway. Compared to regular PSA screening, the 
use of mpMRI as a triage test followed by MRIGB can substantially reduce the risk 
of overdiagnosis and improve the harm-benefit balance, while maximizing prostate 
cancer mortality reduction and QALYs gained.
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INTRODUCTION
The standard and widely used method for the detection of prostate cancer is offering 
transrectal ultrasound-guided biopsy (TRUSGB) for men with an elevated PSA level 
or abnormal digital rectal examination (DRE). However, this classical pathway is as-
sociated with an underdetection of clinically significant/high-grade prostate cancer 
and overdetection of clinically insignificant /low-grade prostate cancer 1, which can 
lead to an unnecessary biopsy, overdiagnosis, and overtreatment. The TRUSGB is 
also associated with a higher rate of misclassification of grades as compared to mag-
netic resonance imaging-guided biopsy (MRIGB) that can lead to under or overtreat-
ment 2. Furthermore, TRUSGB is associated with increased risk of complications 
like bleeding and pain 3, which can lead to increased health care costs and even-life 
threatening sepsis 4. Therefore, looking for an alternative diagnostic pathway that 
can minimize the risk of overdiagnosis and maximizes the prostate cancer mortality 
reduction should be at urge.
Using a multi-parametric magnetic resonance imaging (mpMRI) as a triage test fol-
lowed by MRIGB may reduce the risk of overdiagnosis and overtreatment. Several 
studies reported that the use of mpMRI and MRIGB is superior to a regular pathway 
1,5,6. The MRI pathway is characterized by having high sensitivity for clinically sig-
nificant prostate cancer, and low sensitivity for insignificant cancer 7-9, and reduces 
misclassification rate of grade at biopsy compared to TRUSGB2.  Furthermore, by 
using this pathway, a substantial amount of unnecessary biopsies can be avoided 6.
Although various studies reported that the use of mpMRI and MRIGB can reduce 
the detection of indolent prostate cancer, there is no study so far that quantifies 
the exact effect of this strategy on the risk of overdiagnosis as well as its effect 
on prostate cancer related death. However, estimation of the long-term effects of 
screening such as overdiagnosis is unlikely from trial data. Therefore, the aim of this 
modeling study was to determine the effects of mpMRI and MRIGB as compared to 
TRUSGB in a population-based prostate cancer screening setting.
MATERIALS AND METHODS
MISCAN Model
The micro-simulation screening analysis (MISCAN) prostate cancer model 10-12 was 
used to evaluate the long-term effects of  prostate cancer screening using regular 
pathway (positive PSA test followed by TRUSGB) vs MRI pathway (positive PSA test 
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followed by mpMRI and MRIGB). Microsimulation is a modeling technique that typi-
cally uses a large sample size of individual units (microunits), each with a unique 
set of attributes, and allows for simulations of downstream events on the basis of 
predefined states and the transition probabilities between those states over time13. 
Likewise, MISCAN prostate model is a stochastic model that simulates individual life 
histories, natural history of prostate cancer, effect of treatment at baseline (without 
screening), and the effect of screening. Each individual in the simulation starts 
with no prostate cancer, and through time there is a chance to transit to preclinical 
prostate cancer. There are eighteen pre-clinical detectable states with a combination 
of three stages (T1, T2, and T3), three Gleason scores (7, less than 7, and greater than 
7), and two metastatic states (whether or not the cancer is metastasized). From each 
pre-clinical state, the tumors can progress to a more advanced state, can be clinically 
diagnosed, or be screen detected (Supplementary Figure 1).
After detection, the person is assigned to either radical prostatectomy (RP), radia-
tion therapy (RT), or Active surveillance (AS). Distribution of the treatments depends 
on age, stage, and Gleason score as described before 14-16. Baseline survival (in the 
absence of treatment) from a clinical diagnosis of prostate cancer was modeled by 
fitting a Cox model to Surveillance, Epidemiology, and End Results (SEER) survival 
data from the pre-PSA era (1983-1986), as described in a previous study 14. The effect 
of treatment on survival for localized prostate cancer cases was modeled using a 
hazard ratio of 0.56 for those who received RP as compared with those without 
treatment 17. The same effect was assumed for RT. For metastasized prostate cancer 
cases, it was assumed that palliative treatment has no effect on survival.
The benefit of PSA screening on prostate cancer mortality was modeled using a 
lead time dependent cure probability (mortality benefit increases with lead time). 
Lead time is the years by which detection of the cancer is advanced by screening 
compared with the clinical situation16. If a man is cured, he will not die from pros-
tate cancer; but if he is not cured the date and cause of death are not changed due 
to earlier detection by screening. Death from other causes was modeled based on 
Dutch life table 18.
The MISCAN prostate model was calibrated to European Randomized Study of 
Screening for Prostate Cancer (ERSPC) data as has been described before 12. In order 
to account the younger age groups (50-54 years), the model was also calibrated to 
prostate cancer incidence among the Dutch population between 1989 and 2013 from 
age 50 to age 75 (5-years categories), and the observed prostate cancer mortality 
over the same period was used for validation 19. Further descriptions about the four 
75
Comparative effectiveness of mpMRI and MRI-guided biopsy vs regular biopsy
components of MISCAN prostate model (demography, natural history, screening 
and treatment) can be found at https://cisnet.flexkb.net/mp/pub/CISNET_ModelPro-
file_PROSTATE_ERASMUS_001_12152009_69754.pdf
Screening strategy
In our previous study, we compared more than 200 population-based prostate can-
cer screening strategies, and we found that screening with 3 years interval at ages 
55-64 would be the optimum screening strategy 19. All men with an elevated serum 
PSA level (cut-off 3ng/mL) were referred to TRUSGB in that study. Those who were 
positive at TRUSGB were assigned to either RP, RT or AS according to the treatment 
distribution mentioned before. The biopsy compliance rate after a positive screen 
test result was assumed to be 90%, with a sensitivity of 90% as observed in the ERSPC 
Rotterdam data 20,21. An 80% screening attendance rate was assumed. The total num-
ber of biopsies was calculated by using the number of screen detected cancers and a 
mean positive predictive value of 22.7% of a biopsy in the screen arm of the ERSPC 
21 and by using the number of clinically detected cancers and the positive predictive 
value of 35.8% of a biopsy in the control arm 22.
In the present study, we included mpMRI as a triage test to this screening strategy 
(screening with 3-year intervals at ages 55-64) for those men with an elevated PSA 
level (cut-off 3ng/mL) before referring them to a biopsy (MRIGB) (Figure 1). PIRADS 
scores of 3-5 were considered positive for the mpMRI test. It is important to note that 
we didn’t use a combined biopsy, rather those men with positive mpMRI tests were 
subjected only to an MRI-guided biopsy (no systematic biopsy). The same screening 
attendance and biopsy compliance were assumed as in the regular pathway. A posi-
tive predictive value of 58% 23 was assumed to calculate the total number of biopsies 
in this strategy. Men positive at MRIGB were assigned to the same treatment options 
as in TRUSGB. Grade specific sensitivity values for mpMRI and MRIGB were mainly 
based on literature that used meta-analysis (Table 1). Although a very recent meta-
analysis reported by Drost etal, 202024 was not included in our study, most of the 
test sensitivity parameter values reported in that study are within the range of the 
values that we used for our sensitivity analysis.
We also accounted for misclassification of grades both in the MRIGB and regular 
biopsy. In our study misclassification of grades represents only wrong classification 
of clinically significant cancer in to insignificant cancer at biopsy. For the MRIGB we 
used an 8.7% misclassification rate based on Ahdoot et al 2. For the regular biopsy 
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16.8%, 36.3% and 60% of misclassification were reported 2,25,26, and we used the inter-
mediate 36.3%.
We compared the two strategies in terms of a harm-benefit ratio (overdiagnosis per 
death averted), reduction of overdiagnosis, reduction of number biopsied, detection 
of clinically significant cancer, death averted, life-years gained, life-years gained 
(LYG) per death averted, QALYs gained and QALYs gained per death averted. In this 
study, clinically significant prostate cancer was defined as Gleason score 7 or more 
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Figure 1. Schematic representation of the MRI pathway (M) and regular pathway (R). 
mpMRI- multi parametric magnetic resonance imaging ; MRIGB- magnetic resonance imaging-guided biopsy; 
MRI- magnetic resonance imaging; TRUSGB- transrectal ultrasound-guided biopsy 
   



























Figure 1. Schematic representation of the MRI pathway (M) and regular pathway (R). mpMRI = 
multi parametric magnetic resonance imaging ; MRIGB = magnetic resonance imaging-guided 
biopsy; MRI = magnetic resonance imaging; TRUSGB = transrectal ultrasound-guided biopsy.
Table 1. Sensitivity values for the MRI pathway used in the model.
Variable Value Source
Sensitivity of mpMRI for high grade cancer 0.94 (Range 0.70 – 0.97) Sathianathen etal. 201937
Overall sensitivity of mpMRI*
Sensitivity of MRIGB for low grade cancer
0.74  (95% CI 0.66 – 0.81)
0.44 (95% CI  0.26 – 0.64)
de Rooij et al. 201438
Schoots et al. 201529
Sensitivity of MRIGB for high grade cancer 0.91 (95% CI 0.87 – 0.94) Schoots et al. 201529
mpMRI = multi parametric magnetic resonance imaging ; MRIGB= magnetic resonance imaging-guided biopsy. 
* Used as a sensitivity of mpMRI for low grade cancer in our model.
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and clinically insignificant cancer as Gleason score 6 and less 5. In both screening 
strategies, a hypothetical cohort of 10 million men was simulated over a lifetime 
period. All the results are reported per 1000 men.
Quality of life
The quality adjusted life-years (QALYs) were calculated based on the utility estimates 
of given health states where patients remain for a certain period of time. The utility 
values range between 0 (death) and 1 (perfect health), and one minus the utility 
value gives a loss in utility at each health state. By multiplying the number of men 
in a given health state with the loss in utility and the duration of the health state, 
the loss in quality of life was calculated. The utility estimate (0.96) and duration 
(1 week) for mpMRI were based on Grana et al 27. There is evidence that MRIGB is 
associated with less frequent adverse outcomes compared with TRUSGB3. Therefore, 
we assumed 50% lower disutility for MRIGB compared with that of TRUSGB. All other 
utilities and durations were based on our previous study 12 (Supplementary Table 1).
Sensitivity analysis
To check the robustness of our results, we performed a one-way sensitivity analysis 
on the harm-benefit ratio (overdiagnosis per death averted) of the MRI pathway. 
Because the performance and interpretation of both mpMRI and MRIGB are highly 
influenced by the specialists (radiologist or urologist) skills, we varied the test sen-
sitivity parameters for the analysis using the 95% confidence intervals indicated in 
Table 1. A threshold analysis was also performed on QALYs per death averted by 
changing the baseline sensitivity values of the mpMRI and MRIGB simultaneously.
RESULTS
Base model:
The total numbers of men referred to a biopsy were 396 and 278 for the regular 
and the MRI pathway respectively, a 30% reduction (Table 2). Our model predicted 
16 overdiagnosed cases for the regular pathway and 9 (43% reduction) for the MRI 
pathway (overdiagnosed cancer was defined as a prostate cancer detected during 
screening but would not have been clinically diagnosed during the man’s life time 
in the absence of screening). The model predicted a 2.7% higher prostate cancer 
mortality reduction for the MRI pathway than the regular pathway (8.77 vs 8.53). 
The MRI based screening was also associated with a lower harm-benefit ratio (overdi-
agnosis per cancer death averted) than the regular screening (1.0 vs 1.8). Our model 
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predicted a higher LY gained (85 vs 81.6) and  QALYs gained (80.2 vs 77)  in the MRI 
pathway than the regular screening pathway.
Clinically significant prostate cancer was detected in 51.3 men in the MRI pathway, 
as compared with 36 in the regular pathway (30% increment in the detection rate of 
clinically significant prostate cancer). In contrary, fewer men were diagnosed with 
clinically insignificant prostate cancer in the MRI pathway than the regular pathway 
(59 vs 80.8), which resulted in a 27% reduction. However, the MRI pathway was 
also associated with an 11% risk of missing clinically significant cancer due to not 
performing biopsy in the mpMRI negative patients.
Sensitivity Analysis:
After varying the baseline sensitivity values of the MRI pathway, using the 95% con-
fidence intervals or ranges, the harm-benefit ratio (overdiagnosis per death averted) 
remained lower in the MRI pathway than the baseline value (1.8) of the regular 
pathway (Figure 2). The threshold analysis indicated that when the baseline test 
sensitivity values of the MRI pathway were changed by 14% simultaneously, the 
QALYs/death averted became the same for the two strategies (Figure 3). To be the 
Table 2. Predictions of the effects of prostate cancer screening for men between age 55-64 at 3 






Number of men biopsied 396 278 118 (-30%)
Total number of clinically insignificant cancer1 
detected at biopsy
80.8 58.9 21.9 (-27%)
Total number of clinically significant cancer2 
detected at biopsy
36.0 51.3 15.3 (+29.8%)
Percent clinical significant cancer missed in 
the MRI-pathway due to reduction in biopsies
- 10.8 % -
Number overdiagnosed3 15.6 8.9 6.7 (-43%)
Number of prostate cancer deaths averted 8.53 8.77 0.24 (+2.7%)
Overdiagnosed cases per death averted 1.8 1.0 0.8 (- 44%)
Life-years gained







Quality adjusted life-years gained







1 clinically insignificant cancer was defined as Gleason score 6 and below (it contains both screen detected and 
interval cancer);
2 clinically significant prostate cancer was defined as Gleason score 7 or more (it contains both screen detected 
and interval cancer)
3 overdiagnosed cancer was defined as a prostate cancer detected during screening but would not have been 
clinically diagnosed during the man’s life time in the absence of screening.
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QALYs per death averted in favour of the MRI pathway, the sensitivity of mpMRI and 
MRIGB for clinically significant prostate cancer should be higher than 81% and 78% 
respectively; Whereas, for that of clinically insignificant prostate cancer it should be 
lower than  84% and 50% respectively.
DISCUSSION
The benefit of prostate cancer screening in reducing advanced stage disease or mor-
tality is counterbalanced by the risk of overdiagnosis and overtreatment 28. In our 
study, when mpMRI was applied after a positive PSA test and followed by MRIGB, 
the risk of overdiagnosis was decreased substantially (by 43%) compared with the 
regular screening. This result can be taken confirmatory for previous studies that 
proposed the use of mpMRI and MRIGB as a potential means to reduce the risk of 
overdiagnosis. The lower harm-benefit ratio predicted in the present study could 
0,6 0,7 0,8 0,9 1 1,1 1,2 1,3 1,4
sens. MRIGB high grade
sens. mpMRI low grade
sens. mpMRI high grade
sens. MRIGB low grade
Overdiagnosis per death averted in the MRI pathway  
Upper bound
Lower bound
Figure 2. Tornedo diagram of one-way sensitivity analysis on the harm-benefit ratio (over diagno-
sis per cancer death averted) for the MRI pathway. sens.MRIGB low grade- sensitivity of magnetic 
resonance imaging-guided biopsy for low grade prostate cancer; sens.MRIGB high grade- sensi-
tivity of magnetic resonance imagingguided biopsy for high grade prostate cancer; sens.mpMRI 
low grade- sensitivity of multi-parametric magnetic resonance imaging for low grade prostate 
cancer; sens.mpMRI high grade- sensitivity of multi-parametric magnetic resonance imaging for 
high grade prostate cancer.
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also inform policymakers about the role of MRI in a population-based prostate 
cancer screening.
When the MRI pathway was used instead of the regular pathway, 30% of men 
avoided biopsies. A recent study by Kasivisvanathan et al 5 reported a 28% biopsy 
reduction due to the use of mpMRI and MRIGB. As compared to the regular path-
way, the MRI pathway was also associated with a 30% higher detection rate and 
27% lower detection rate for clinically signifi cant and insignifi cant prostate cancer, 
respectively. A meta-analysis 29 concluded that MRIGB has a higher detection rate 
for clinically signifi cant prostate cancer and a lower detection rate for insignifi cant 
cancer compared with TRUSGB. More specifi cally, Siddiqui et al 30 reported MRIGB 
increases the detection of high risk cancer by 30% (compared to TRUSGB), and Leest 
et al 31 indicated TRUSGB would over detect insignifi cant cancer in 20%. The number 
(percentage) of clinically signifi cant cancers reported in our study (in both path-
ways) are lower than the number reported by Kasivisvanathan et al. 2018, who used 
the same defi nition. The main reason for this discrepancy could be the difference 
in population characteristics of the two studies. For instance, the upper age limit 
included in the present study was 64 years, whereas in Kasivisvanathan et al. 2018 
the mean age was 64±7. Therefore, the older age groups in the Kasivisvanathan et al. 
Figure 3. A threshold analysis diagram indicating the QALYs per cancer death averted continues 
to be in favor of the MRI pathway when the sensitivity values of the MRI pathway were changed 
simultaneously by up to 14% (this means increasing the sensitivities of mpMRI and MRIGB for 
low grade cancer and decreasing for high grade cancer by up to 14% simultaneously). Increas-
ing the sensitivity for low grade cancer means detecting more Gleeson 6 cancer and decreasing 
the sensitivity for high grade cancer means detecting fewer clinically signifi cant cancer which 
reduce the QALY per death averted.
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2018 may contribute to the higher number of high grade cancers (grade 7 and above) 
than reported in our study. Although it is difficult to directly compare our results 
with the above studies (because of differences such as, population characteristics, 
follow-up period and screening strategy), the general conclusion is the same: the 
use of mpMRI and MRI guided biopsy is superior over that of the regular pathway.
Using of the MRI pathway resulted in an increased LYG, QALYs gained, and prostate 
cancer death averted compared to the regular pathway. The increased in LYG and 
mortality benefit in the MRI pathway can be explained by the increased detection 
of clinically significant cancer (by about 30%), and the lower misclassification rate 
of grades by MRIGB (compared to TRUSGB), that were included in our model. On 
the other hand, the lower detection rate of clinically insignificant cancer in the MRI 
pathway could explain the higher QALYs gained. However, the MRI pathway also 
failed to detect around 11% of clinically significant cancer, that would be detected 
in the regular pathway, and this could explain the smaller difference in mortality 
benefit between the two strategies. This percentage is in agreement with a pre-
vious study by Pokorny et al 6. The small QALYs difference reported between the 
two strategies may raise a question of whether the MRI-pathway can be an efficient 
strategy, especially in relation to the initial additional expenditures required in the 
MRI-pathway. However, a substantial amount of biopsies were avoided as a result of 
using the MRI pathway, and this could compensate for the additional expenditures.
Our prediction of the lower harm benefit ratio (overdiagnosis per death averted) for 
the MRI pathway than the regular pathway was robust to the sensitivity analysis 
(Figure 2). It is also important to note from the figure that, increasing the sensitiv-
ity of mpMRI and MRIGB for high grade cancer resulted in a more better harm 
benefit ratio, and lowering theses sensitivities relatively worse the ratio. In contrary, 
lowering the sensitivity of mpMRI and MRIGB for low grade cancer makes the ratio 
more better, and increasing these sensitivities makes the ratio relatively worse. The 
threshold analysis showed that when the baseline test sensitivity values of the MRI 
pathway were changed by 14% simultaneously (this means increasing the sensitivi-
ties of mpMRI and MRIGB for low grade cancer and decreasing for high grade cancer 
by 14% simultaneously), the QALYs per death averted became the same for the two 
strategies. This may signify the importance of adhering to proper imaging protocol 
as well as interpretation by the radiologist/urologist. A review by Stabile eta al 32 
indicated that there are various factors affecting the performance of mpMRI and 
MRIGB, among these radiologists’ reading experience and urologists’/radiologists’ 
biopsy experience were the main ones.
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An important strength of this study is that we were able to quantify the effect of 
MRI based prostate cancer screening on the risk of overdiagnosis, which is obviously 
not observable in trial studies. We also quantified the effect of the MRI pathway on 
the harm-benefit ratio (overdiagnosis per death averted) as compared to the regular 
pathway, which was also not reported in previous studies. Furthermore, we were 
able to evaluate the MRI pathway in a population based screening setting. Although 
our model is calibrated to the Dutch prostate cancer incidence, the results may also 
be extrapolated to other western populations with similar prostate cancer incidence 
trends. Study shows that in Western Europe, the incidence of prostate cancer has 
been on the rise.33.
Our study has also certain limitations. First, we assumed the same mortality benefit 
for radiation therapy as that of radical prostatectomy, since there is no clinical trial 
that compared the two treatment directly. We also assumed that treatment options 
will not change in both strategies. However, treatment behavior may change in the 
future, such as more active surveillance than now. Cost is another important factor 
which was not included in this study. However, avoidance of biopsies and subsequent 
biopsy related complications and treatment costs, probably make the MRI pathway 
cost-effective or at least compensate its additional costs. Various studies, though 
not population-based studies, indicated that the inclusion of mpMRI after a posi-
tive PSA test followed by MRI-guided biopsy is cost-effective compared to a regular 
prostate cancer screening pathway34-36. Future studies are needed to evaluate this in 
a population-based screening settings. Lastly, a probabilistic sensitivity analysis was 
not included in our study: only a one-way sensitivity analysis and threshold analysis 
were included.
In conclusion, our modeling results indicated that the use of mpMRI after a positive 
PSA test followed by MRIGB can substantially reduce the risk of overdiagnosis and 
improve the harm-benefit ratio, while maximizing prostate cancer mortality reduc-
tion and QALYs gained, as compared to the regular screening pathway.
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Supplementary table 1. Utility estimates and durations of the various health states, obtained 
from a previous study12.
Health state Utility estimates (range) Duration
PSA screening attendance 0.99 (0.98-1.00) 1 week
Diagnostic phase 0.90 (0.87-0.94) 3 weeks
Diagnosis 0.80 (0.75-0.85) 1 month
Radical prostatectomy
At 2 months after procedure






At 2 months after procedure
At > 2 months to 1 year after procedure
0.73 (0.71-0.91)
0.78 (0.61-0.88)
Active surveillance 0.97 (0.85-1) 7 years
Postrecovery period 0.95 (0.93-1.00) 9 years
Palliative therapy 0.60 (0.24-0.86) 30 months
Terminal illness 0.40 (0.24-0.56) 6 months
87








































Supplementary Figure 1.The MISCAN prostate cancer model. The model also contains a dis-
tinction between local and distant states, but for the sake of simplicity it is not illustrated here. 
T- tumor stage ; G - Gleason score
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Background: The introduction of multiparametric magnetic resonance imaging 
(mpMRI) and MRI-guided biopsy has improved the diagnosis of prostate cancer. 
However, it remains uncertain whether it is cost-effective, especially in a population-
based screening strategy.
Methods: We used a micro simulation model to assess the cost-effectiveness of an 
MRI-based prostate cancer screening in comparison to the classical prostate specific 
antigen (PSA) screening, at a population level. The test sensitivity parameters for the 
mpMRI and MRI-guided biopsy, grade misclassification rates, utility estimates, and 
the unit costs of different interventions were obtained from literature. We assumed 
the same screening attendance rate and biopsy compliance rate for both strategies. 
A probabilistic sensitivity analysis, consisting of 1000 model runs, was performed to 
estimate a mean incremental cost-effectiveness ratio (ICER) and assess uncertainty. 
A €20,000 willingness to pay (WTP) threshold per quality adjusted life year (QALY) 
gained, and a discounting rate of 3.5% were considered in the analysis.
Results: The MRI based screening improved the life-years (LY) and QALYs gained 
by 3.5 and 3 respectively in comparison to the classical screening pathway. Based 
on the probabilistic sensitivity analyses, the MRI screening pathway leads to total 
discounted mean incremental costs of €15,413 (95% confidence interval (CI) of 
€14,556 - €16,272) compared to the classical screening pathway. The corresponding 
discounted mean incremental QALYs gained was 1.36 (95% CI of 1.31-1.40), resulting 
in a mean ICER of €11,355 per QALY gained. At a WTP threshold of €20,000, the MRI 
screening pathway has about 84% chance to be more cost-effective than the classical 
screening pathway.
Conclusions: For triennial screening from age 55 to 64, incorporation of mpMRI as 
a reflex test after a positive PSA test result with a subsequent MRI-guided biopsy has 
a high probability to be more cost-effective as compared with the classical prostate 
cancer screening pathway.
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BACKGROUND
Despite the presence of compelling evidence regarding the beneficial effects of pros-
tate specific antigen (PSA) screening from a trial and modeling studies1-3, almost no 
country implemented PSA screening at a population level4. This is mainly due to the 
fact that PSA screening is associated with high risk of overdiagnosis and overtreat-
ment. However, the European Urology of Association (EAU) recently stated that the 
European union can no longer overlook prostate cancer, and the introduction of PSA 
screening at a European level need to be rediscussed by taking in to consideration 
the current evidences about prostate cancer screening5. A recent brief correspon-
dence to the European Association of Urology (EAU) emphasized the importance of 
introducing organized PSA screening at a population level in order to reduce mortal-
ity from prostates cancer6. The authors indicated that multi- parametric magnetic 
resonance (mpMRI) should be used as a reflex test after a positive PSA test result to 
select men for biopsy.
The introduction of mpMRI and targeted biopsy has improved the diagnosis of pros-
tate cancer. Several studies reported that the use of mpMR as a triage before biopsy 
and followed by MRI-guided biopsy can substantially reduce the detection of low-
grade prostate cancers and also result in a better detection of clinically significant 
cancers compared to the classical screening with an upfront transrectal ultrasound 
guided biopsy (TRUSGB) for all men with a positive PSA test result7-11. While the 
benefits of using mpMRI with a subsequent MRI targeted biopsy has become more 
clear, its cost-effective remains uncertain, especially for a screening strategy at a 
population level.
Although some studies reported the cost-effectiveness of mpMRI and subsequent tar-
geted biopsy12-15, to our knowledge, no study has yet quantified the cost-effectiveness 
in a  population-based screening strategy, particularly in the European situation. 
Screening at a population level should have a clear starting and stopping age of 
screening and intervals to screen. A study by Barnett et al.,16 that modeled screening 
from 55 to 69 at 2 years intervals reported the cost-effectiveness of mpMRI  and 
targeted fusion biopsy. However, the setting is in the US, where the costs of MRI are 
much different from the costs in Europe. The aim of this study was to investigate 
the cost-effectiveness of MRI based prostate cancer screening pathway compared 
to the classical screening pathway at a population level, using a base model which 
was calibrated to the European Randomized study of Screening for Prostate Cancer 
(ERSPC) data and Dutch prostate cancer incidence and mortality data17. In this study, 
the MRI screening pathway represents for a positive PSA test (≥3ng/mL) followed by 
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mpMRI test and MRI-guided biopsy (for those men positive on mpMRI test), whereas 




In the present study the micro simulation screening analysis (MISCAN) prostate 
cancer model was used3,18,19. Taking variation in to account, the model simulates life 
histories for each individual starting from birth to death. Everyone in the simula-
tion starts with no prostate cancer. Once a malignant prostate tumor initiated in any 
individual in the model, the progression of the cancer is simulated as a sequence 
of preclinical and clinical states. In combination with 3 stages (T1, T2 and T3), 3 
Gleason scores (7, less than 7 and greater than 7), and 2 metastatic states (local-
regional and distant), the model has 18 pre-clinical states. There is also a chance for 
the tumor to progress from each preclinical state to the next T-stage, or change to 
a higher Gleason score, or it may be clinically diagnosed (Supplementary Figure 1). 
Furthermore, the tumor has a chance to metastasize from a local-regional state into 
a distant state. For every individual, two life histories are projected by the model: 
one without screening and the other with screening. A screen detected cancer that 
would not lead to a clinical diagnosis in case of no screening is considered as an 
overdiagnosed cancer11.
Using Surveillance, Epidemiology, and End Results (SEER) data (1983-1986), baseline 
prostate cancer survival (without screening and localized treatment) in the model 
was determined at clinical diagnosis20. In order to model death other than prostate 
cancer, we used a life table of Dutch population.21. To model the effects of treatment 
on localized prostate cancer, a 0.56 relative risk of dying was assumed for radical 
prostatectomy (RP) as  compared to watchful waiting22. We assumed the same treat-
ment benefit for radiation therapy (RP). The distributions of treatments were based 
on age, stage, and Gleason score2,23. The benefit of PSA screening on prostate cancer 
mortality was simulated as a function on lead time based on a lead time-dependent 
cure probability.2 The years by which cancer detection using screening precede clini-
cal detection is termed as a lead time11. Detail information about the model including 




Cost-effectiveness of MRI-based prostate cancer screening
Screening protocol
The screening intervals, start and end age in the present study was based on the 
optimal screening strategy reported in a cost-effectiveness analyses using the same 
base model, which is from age 55-64 at 3 years interval with an 80% screening at-
tendance17. A 90% biopsy compliance rate with a biopsy sensitivity 90% was assumed 
based on the ERSPC Rotterdam data24,25. We kept this screening protocol for the 
classical screening pathway of the current study. For the MR screening pathway, we 
added mpMRI as triage test between a positive PSA test and biopsy. This means, men 
after a positive PSA test were further selected using an mpMRI test before biopsy, 
and only those men positive at mpMRI (PIRADS scores of 3-5) went to biopsy. Fur-
thermore, for the MRI screening pathway, we replaced the TRUSGB with MRI-guided 
biopsy (Supplementary Figure 2). The screening attendance rate and biopsy compli-
ance rate that we used in the MRI screening pathway are the same as in the classical 
screening pathway. The test sensitivity parameters for the mpMRI and MRI-guided 
biopsy were obtained from literature, mainly meta-analyses (Table 1). Misclassifica-
tion of grades (misclassifying a clinically significant cancer into an insignificant 
cancer at biopsy) was also included in the model both for the MRI-guided biopsy 
and TRUSGB. We used an 8.7% misclassification rate for the MRI-guided biopsy8. For 
the TRUSGB biopsy we obtained different values from literature 8,26,27, and used the 
intermediate 36.3% (16.8-60%).
Table 1. The test sensitivity values for the MRI pathway, the utility values and durations of the 
health states, and the unit costs of interventions.
Parameters included in the probabilistic sensitivity analyses
Variables Values Sources
Sensitivity of mpMRI for HGC* 0.94 (SD: 0.06) † Sathianathen et al 
201938
Overall sensitivity of mpMRI ** 0.74 (SD: 0.06) † de Rooij et al. 201439
Sensitivity of MRI-guided biopsy for HGC 0.91 (SD: 0.05) † Schoots et al. 201534
Sensitivity of MRI-guided biopsy for LGC# 0.44 (SD:0.05) † Schoots et al. 201534
Unit costs of mpMRI €345 (min=€293, max=€397) ‡ de Rooij et al. 201413
Unit costs of MRIGB €800  (min=€680, max=920) ‡ de Rooij et al. 201413
Unit costs of TRUSGB €247 (min=€210, max=€284) ‡ Heijnsdijk et al 20153
Remaining unit costs in Euro used in the model (common for both strategies)
Variables Values Heijnsdijk et al 20153
PSA screening 35
Staging 290
Radical prostatectomy (RP) 17,119




All the unit costs included in this study were obtained from literature and reported 
in Euros (Table 1). The number of screening visits, positive biopsies, diagnoses, 
treatments, and life years were estimated by the model. In order to determine the 
number of negative biopsies, we calculated the total number of biopsies based on 
detected cancers and a positive predictive value of a biopsy as described on litera-
ture11,17. Indirect costs were not included in this study. A 3.5% discounting rate was 
used for both costs and effects.
Table 1. The test sensitivity values for the MRI pathway, the utility values and durations of the 
health states, and the unit costs of interventions. (continued)
Remaining unit costs in Euro used in the model (common for both strategies)
Variables Values Heijnsdijk et al 20153
Active surveillance (AS) 2,303
Follow up 218
Advanced disease (Palliative treatment) 17,800
Utility values and duration of health states used in the model  
(common for both strategies, except biopsy and mpMRI)





PSA screening attendance 0.99 (1, 0.99) 1 week
mpMRI 0.9640 - 1 week
TRUSGB 0.90 (0.94, 0.87) 3 weeks
MRIGB ¶ 0.95 (0.97, 0.93) 3 weeks
Diagnosis 0.80 (0.85, 0.75) 1 month
RP 0.67 (0.90, 0.56) 2 months
RT 0.73 (0.91, 0.71) 2 months
AS 0.97 (1, 0.85) 7 years
2 months to 1 year RP 0.77 (0.91, 0.70) 10 months
2 months to 1 year RT 0.78 (0.88, 0.61) 10 months
Postrecovery period 0.95 (1, 0.93) 9 years
Palliative therapy 0.60 (0.24, 0.86) 30 months
Terminal illness 0.40 (0.24, 0.56) 6 months
mpMRI = multi parametric magnetic resonance imaging; MRI = magnetic resonance imaging; TRUSGB = trans-
rectal ultrasound-guided biopsy; min = minimum; max = maximum
*HGC= high grade cancer
** assumed as a sensitivity of mpMRI for LGC
#LGC=low grade cancer
† the standard deviations are based on de Rooij et al. 201413
‡ the base value is varied by ±15% for the max and min
¶ Because usually less biopsy complications are associated with MRIGB than TRUSGB, we assumed a 50% lower 
utility loss due to MRIGB than TRUSGB.
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Utilities and Quality of life
Most of the utility values and duration of health states were obtained from litera-
ture18, (Table 1). The loss in utility was calculated by subtracting the utility value 
from 1. The product of the number of men in a given health state with the loss in 
utility and duration of the health state gives the loss in quality of life17.
Analysis
For both strategies, the undiscounted LY gained, QALYs gained, and the number of 
men biopsied were from a single model run. The net effects and costs in each strategy 
were compared with a no screening strategy. The mean discounted total net costs 
of screening, diagnosis and treatment, and palliative care, the mean discounted net 
QALYs gained and the mean total incremental net costs along with 95% CI, the mean 
incremental cost-effectiveness ratio (ICER), and the mean incremental net monetary 
benefit (iNMB) were based on probabilistic sensitivity analyses. To estimate the ICER 
we divided the difference in total net costs between the MRI screening pathway and 
the classical screening pathway by the difference in net QALYs gained between the 
two strategies. A willingness to pay threshold (WTP) of €20,000, which is a common 
Dutch WTP28, was used to determine the cost-effective of a given strategy. If the ICER 
of a given strategy is lower than this WTP, it is cost effective. The mean iNMB was 
calculated by multiplying the incremental net effects (QALYs) with a WTP (€20,000) 
and subtracting the incremental net costs.
In the probabilistic sensitivity analyses, we performed 1,000 simulations in which 
selected model parameters were varied (based on distribution) simultaneously. A 
large sample size (10 million men) was used in each simulation, which eliminated 
stochastic noise in the model. The parameters included in the probabilistic sensi-
tivity analyses were mainly those parameters which are not common in the two 
strategies. This includes the test sensitivity values of mpMRI, sensitivity values 
of MRI-guided biopsy, costs of mpMRI, costs of MRI- guided biopsy, and costs of 
TRUSGB. The test sensitivity values were varied using their base value and standard 
deviation. For the costs, we used a Pert distribution with the most likely (base) value 
and an assumption of ±15% for the minimum and maximum values (Table 1). The 
uncertainty around  utility values and remaining costs were tested only using a 
one-way sensitivity analysis (because of labour constraints). The baseline utility val-
ues were varied using their favourable and unfavourable estimates, obtained from 
literature18, and the costs were varied by ±15%.
For post-processing of the outputs, we used R software together with the Bayesian 
cost-effectiveness analysis (BCEA) and ggplot2 packages to obtain the cost-effec-
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tiveness plain with mean ICER and the cost acceptability curves29. We used Rmisc 
package30 to obtain the mean incremental net costs and effects with their 95% CI 
based on the 1000 model runs for the probabilistic sensitivity analysis.
RESULTS
Undiscounted effects from the base model
For triennial screening from age 55 to 64, the MRI screening pathway resulted in 
additional 3.5 life-years gained and 3 additional QALYs gained per 1,000 men invited 
to screening and followed over their lifetime period. Furthermore, the number of 
biopsied men reduced by 30% when the MRI screening pathway was used (Table 2).
Table 2. Estimated life time screening outcomes and results of probabilistic sensitivity analysis 







Screening outcomes from single run
Number biopsied  396 278 -118 (30%)
Life years gained*  81.5 85 +3.5 (4%)
Quality adjusted life years  gained*  77.2 80.2 +3.0  (4%)
PS-analysis outcome, 3.5%
Discounted
Mean net costs (in €) of *:
Screening  80,118 156,429 +76,311 (49% )
Diagnosis and treatment  317,999 258,206 -59,793   (19% )
Palliative care -60,145 -61,250 -1,105 (2%)
Mean total net costs  337,972 353,385 +15,413 (4.4%)
Mean QALY gained*  24.09 25.45 +1.36  (5.3%)
Mean  Incremental total net costs with 
95% CI in the bracket




Mean Incremental QALYs gained  with 
95% CI in the bracket
 - 1.36 
( 1.31, 1.40 )
+ 1.36 
(1.31, 1.40 )
Mean ICER  - 11,355 +11,355
Mean incremental net monetary benefit 
(iNMB)
 - 11,735 +11,735
CI= confidence interval, M= MRI pathway,  PS-analysis= Probabilistic sensitivity analysis, C= classical pathway 
*Compared to no screening
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Probabilistic sensitivity analysis
The results show that the mean discounted incremental costs of screening, diag-
nosis and treatment, and palliative care of  the MRI screening pathway versus the 
classical pathway were €76,300, €-59, 793, and €-1,105 respectively, resulting in 
a total mean incremental costs of €15,413 (95% confidence interval of €14,556 - 
€16,272) for 1000 men invited. The associated discounted mean incremental QALYs 
gained was 1.36, with a 95% confidence interval of 1.31-1.40 (Table 2). The mean 
ICER of the MRI screening pathway versus classical screening pathway was  €11,355 
(Table 2 and Figure 1). The cost-effectiveness plane (Figure 1) shows the uncertainty 
around the mean ICER estimate, and the majority of the incremental net cost-effect 
pairs gathered in the northeastern part of the plane below the WTP threshold line. 
In the northeast part of the plane, the MRI strategy is more effective and more 
expensive. The probabilities that the incremental cost-effect pairs of the MRI path-
way, compared to the classical screening pathway, to fall in northeast and southeast 
quadrants were 85.2% and 11.3% respectively (Supplementary Figure 3).
The cost-effectiveness acceptability curves at Figure 2 show that the MRI screening 
pathway had a high probability of being more cost-effective (84%) compared with 
the classical screening pathway, using a €20,000 WTP threshold per QALY gained. 
At this WTP threshold the MRI screening pathway has also a positive mean iNMB of 
€11,735 compared with the classical screening pathway (Table 2).
 
Figure 1. Cost-effectiveness plain of the MRI screening pathway versus the classical pathway at a 
WTP threshold of €20,000. In the northeast quadrant the MRI screening pathway is more effec-
tive and more costly: in the southeast quadrant, it is more effective and less costly (dominant): 
in the northwest quadrant, it is less effective and more costly (dominated), and in the southwest 
quadrant, it is less effective and less costly, than the classical screening pathway.
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The one-way sensitivity analysis did not change the ICER substantially, ranging only 
between €10,000 and €13,700 (Supplementary Table 1) Although the change is not 
substantial, the cost-effectiveness became better for the MRI based screening strat-
egy when the utility estimates for biopsy, diagnosis, treatments, palliative care, and 
advanced disease were unfavorable. Similarly, the ICER decreased when the costs of 
staging, treatment, and advanced disease care increased.
DISCUSSION
The results from the model, that accounts for long term prediction of costs and ef-
fects, suggest that the use of MRI screening pathway is more cost-effective than the 
classical prostate cancer screening pathway. The MRI pathway reduced the diagnosis 
and treatment costs by 19% and that of palliative care by 2% in comparison to the 
classical pathway. This reduction of diagnosis and treatment costs is mainly due 
to the lower sensitivity of mpMRI and MRI-guided biopsy for low grade prostate 
cancer that reduces unnecessary biopsy and treatment. Generally, mpMRI and MRI-
guided biopsy have lower sensitivity for low grade cancer and higher sensitivity for 
clinically significant cancer 31-33 than the traditional random biopsy (TRUSGB)34. The 
latter can explain the reduction in the costs of the palliative care reported in the 
current study which in turn reduces the occurrence of advanced prostate cancer 
 
Figure 2. Cost-effectiveness acceptability curves for the MRI screening pathway and classical 
(regular) pathway
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(prostate cancer with clinical symptoms). In comparison to the classical screening 
pathway the MRI pathway also resulted in additional LY gained and QALYs gained. 
Reduction in biopsy procedure, overlooking of low-grade cancer and better detec-
tion of clinically significant cancer 34,35 due to the MRI pathway could explain these 
findings. Whether the MRI screening strategy is cost-effective than the classical 
screening pathway depends on the WTP threshold, and according to our results at 
€20,000 cut-off, the MRI screening pathway is most cost-effective in the majority of 
the model runs (84%) done for the probabilistic sensitivity analyses. The reduction in 
biopsy costs due to avoiding unnecessary biopsies, treatment costs due to avoiding 
overtreatment and the reduction in palliative cares costs due to improved detection 
of clinically significant cancers, and the modest increment of the QALYs gained in 
the MRI screening pathway explain how this strategy leads to a high probability to 
be cost-effective as compared to the regular screening pathway.
Although their screening strategies differed, some published studies showed that 
the use of mpMRI and MRI-guided biopsy is cost-effective 12,13, which is in agreement 
with our findings. A cost- effectiveness analysis from the USA reported a higher 
ICER than the current finding16, and this could be mainly because of the costs of 
MRI in the USA are much higher than the costs in Europe that we used in this study. 
It should be noted that the results may not be directly comparable with the pres-
ent study due to several reasons (such as screening strategies, model performance, 
data used, follow-up period), but the general conclusions are consistent. The 30% 
reduction in biopsy procedure due to the MRI screening pathway in this study is 
consistent with a recent MRI study 10.
Major strength of the present study is that we determined the cost-effectiveness 
of the MRI screening pathway at population level which was not reported before, 
particularly in the European situation. Another strength of the present study is 
that the MISCAN prostate model, we used in this study, includes the unobservable 
prostate cancer natural history, and also allows us to estimate effects of screening 
over life time periods, which is unlikely in trial studies, and most of other modeling 
cost-effectiveness studies12,13,15.
This study is also subjected to certain limitations. First, we did not account costs 
of biopsy complications. There is more risks of complication and subsequent in-
crement of health care costs due to TRUSGB biopsy than MRI guided biopsy 36,37. 
Therefore, the cost-effectiveness would be even more in favor of the MRI screening 
pathway if these costs were included. Second, assumptions were made for certain 
model parameters when data is not available. Another limitation of the present 
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study is that treatment options were assumed to be the same and will not change in 
both strategies. However, how diagniosed cancer should be treated may depend on 
the MRI outcome, and also treatment behavior may alter in time. More studies are 
needed to assess whether it is effective to make treatment decisions based on MRI 
test results.
In conclusion, our study suggests that for triennial screening from age 55 to 64 
incorporating mpMRI as a triage test in prostate cancer screening before biopsy with 
subsequent MRI-guided biopsy has a high probability to be more cost-effective than 
the classical screening pathway.
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Supplementary Table 1. Results of varying the utility estimates and unit costs using a one way 
sensitivity analysis (each outcome is based on a single run).
ICER* in €
Utilities Base case 
(=11,135)
Favorable# Unfavorable#
utility for screening attendance Base 11,125 11,135
utility for biopsy Base 12,970 10,067
utility for diagnosis Base 11,366 10,914
utility at 2 months after RP treatment Base 11,870 10,815
utility at 2 months after RT treatment Base 11,951 11,052
utility at 2 months to 1 year after RP treatment Base 13721 10,177
utility at 2 months to 1 year after RT treatment Base 13,741 10,105
utility for AS Base 12,910 10,490
utility for post recovery period Base 13,042 10,215
utility for Palliative therapy Base 12,343 10,664
utility for terminal illness Base 12,569 10,087
Costs +15% -15%
Costs of PSA test Base 11,164 11,107
Costs of staging Base 10,852 11,253
Costs of RP Base 10,658 11,530
Costs of RT Base 10,476 11,794
Costs of AS Base 10,019 12,253
Costs of follow-up Base 10,016 11,255
Costs of advanced case Base 11,086 11,267
AS = active surveillance, ICER= incremental cost-effectiveness ratio, RP = radical prostatectomy, RT= radiation 
therapy
# the utility estimates are varied using the favorable and unfavorable values based on literature14
*The incremental cost effectiveness ratio of the MRI screening pathway as compared to the regular pathway
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Supplementary Figure 1. Progression/transition of prostate cancer from no prostate cancer to 
different preclinical and clinical states. Each states in the model can also be local or distant, but 
for simplicity this is not included in the figure. T stands for tumor stage and G for Gleason score
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Supplementary Figure 3. The probabilities that the incremental cost-effect pairs of the MRI 











This thesis contains three main parts with various research questions, and this 
general discussion begins with descriptions of the answers to the research questions 
raised in each part of the thesis by summarizing the main findings. This is followed 
by further discussion and interpretation of the results and indication of future re-
search directions. Finally, the main conclusions of this thesis and recommendations 
will be given.
7.1 ANSWERS TO THE RESEARCH  QUESTIONS
Part 1. PSA Screening for prostate cancer
Research question 1: Can models provide additional information about PSA screen-
ing beyond the observed data of randomized controlled trials?
The ERSPC, PLCO and CAP trials were the three large randomized clinical trials aim-
ing to study the effect of prostate cancer screening. However, in general, trials are 
limited in follow-up time to assesses the long-term effects of screening, especially 
when the lead time is long like the case of prostate cancer. Furthermore, trials lack 
alternative screening designs which are essential for finding an optimal screening 
strategy that can lead to a better balance between the harms and benefits.
In this study using the MISCAN prostate model, that includes quality of life esti-
mates, we indicated that the harm-benefit ratio (overdiagnosis per cancer death 
averted) of a PSA based screening between the age group 55-63 is better than the 
broad 55-69 age group (the age group used in the recent USPSTF ‘C’ recommendation 
about prostate cancer screening, mainly based on trial data). The ratios were 3.2 and 
5.4 respectively. The harm-benefit ratio was worst for the age group 64-69 (7.0).
In the same chapter, we also assessed whether the recently published Cluster Ran-
domized Trial of PSA Testing for Prostate Cancer (CAP) changes the existing evidence 
for PSA testing by replicating the trial using MISCAN model. After replicating the 
trial with available data, we predicted a 0.94 prostate cancer mortality ratio over the 
period of 10 years, the same follow-up period as the trial. The prediction was very 
close to the observed mortality ratio. To account for the effect of length of follow 
up period, we also extended the projection to 15 and 20 years, but this did not 
change the prediction. Based on this we conclude that although the CAP trial did not 
show statistically significant differences in prostate cancer mortality after 10 years 
of follow-up, there may still be a mortality benefit.
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Research question 2: Can we find an optimal cost-effective prostate cancer screening 
strategy at population level? If so, what are the associated long-term harms and 
benefits?
In this study, using the micro-simulation model, we assessed the harms, benefits, 
and cost-effectiveness of more than 200 alternative PSA based screening strategies, 
differing by screening start age (50, 51, 52, 53, 54, and 55), stop age (51-69), and 
intervals (1, 2, 3, 4, 8, and single test), in which efficacy was based on ERSPC trial. 
We found that the most optimum screening strategy would be screening between 
ages 55–64 at 3 years intervals, with an incremental cost-effectiveness ratio (ICER) of 
€19,733 per quality adjusted life-year (QALY). A 27% prostate cancer mortality reduc-
tion and 28 life-years gained (LYG) per 1000 men were predicted for this strategy. 
The associated risk of overdiagnosis for men detected with prostate cancer because 
of screening was 36% (11/30).
Part 2. Magnetic resonance imaging in prostate cancer screening
Research question 3: does the use of mpMRI as a triage test followed by an MRI-guided 
biopsy result in a better harm-benefit balance compared to regular PSA screening?
Major concerns with PSA based prostate cancer screening are the associated risk of 
overdiagnosis and subsequent overtreatment that affect the quality of life of a per-
son. Using mpMR as a reflex test followed by MRI-targeted biopsy has been suggested 
to decrease the detection of low grade cancer and improved detection of clinically 
significant prostate cancer. However, its actual effect on the risk of overdiagnosis 
need to be quantified.
For this study, we found test sensitivity parameters for mpMRI and MRI-guided 
biopsy from literature, mainly meta-analysis. Since the MRI-guided biopsy has a 
better classification of graded as compared to TRUSGB, we also included different 
misclassification rates for the two pathways, based on values from literature. Using 
the MISCAN model we estimated a reduction of overdiagnosis, harm-benefit ratio, 
reduction of biopsies, detection of clinically significant and insignificant cancer, 
prostate cancer death averted, LYs, and QALYs gained for both strategies (the MRI 
screening pathway and regular screening pathway).
We found that the MRI screening pathway results in a 43% reduction in the risk of 
overdiagnosis compared to the regular screening pathway. A better harm-benefit 
ratio (overdiagnosis-per cancer death averted) was also predicted for the MRI path-
way. The corresponding biopsy reduction, due to using mpMRI test as a triage before 
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biopsy, was 30%. A modest increment in prostate cancer mortality reduction, LYs, 
and QALYs gained was also seen in the MRI pathway compared to the regular screen-
ing pathway.
The results show that the use of mpMRI as a reflex test followed by an MRI-guided 
biopsy can substantially reduce the risk of overdiagnosis and improve the harm-ben-
efit balance as compared to the regular prostate cancer screening-biopsy pathway.
Research question 4: Is the MRI-based prostate cancer screening more cost-effective 
than the regular screening pathway?
In this study, we assessed whether the MRI screening pathway (increasing cost) could 
also be more cost-effective than the regular prostate cancer screening pathway. We 
projected the net costs and effects (compared to no screening) for both screening 
strategies (triennial screening between the age 55 to 64 without MRI and with MRI). 
We found that the MRI screening pathway resulted in total discounted mean incre-
mental costs of €15,413 (95% confidence interval (CI) of €14,556 - €16,272) and a 
corresponding 1.36 (95% CI of 1.31-1.40) discounted mean incremental QALYs gained 
as compared to the regular screening pathway. The probability that the MRI screen-
ing pathway is more cost-effective was around 84% at a WTP threshold of €20,000.
We conclude that when mpMRI is used after a positive PSA test and followed by MRI 
guided biopsy, it has a high probability to be more cost-effective than performing 
the regular PSA based screening, and below the suggested CEA cut-off.
Part 3: Online decision tools
Research question 5: Can we develop an online tool, with long term predictions, for 
patient-physician decision about prostate cancer screening?
Although trials have shown efficacy, and reasonable harm-benefit ratios were in-
dicated using modelling studies, there is no population based PSA screening yet. 
Existing guidelines on prostate cancer screening recommend individual PSA testing.
In this study, the MIcro-simulation SCreening ANalysis (MISCAN) model was used for 
predictions of different (long-term) outcomes that are included in a “personalised 
calculator”. Age, prostate specific antigen (PSA) level, PSA test history, and Gleason 
scores were used as predictors in the model.
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Based on the model prediction, we found that outcomes describing the risk of 
having (high grade) prostate cancer, prostate cancer related death, overdiagnosis, 
and expected life-years gained substantially varied across the different predictors 
included in the model. Using these model outputs, we developed a tool/calculator 
that can inform patients and their physicians about the harms and benefits of at-
tending PSA test, undergoing biopsy, and taking treatment.
7.2 INTERPRETATION OF THE FINDINGS
PSA Screening for prostate cancer
The implementation of PSA based screening for prostate cancer at a population-
level remains debated despite the substantial prostate cancer related mortality 
reduction observed in the European Randomized Study of Screening for Prostate 
Cancer (ERSPC)1,2 . This is mainly because the beneficial mortality effect is counter 
balanced by the risk of overdiagnosis and subsequent treatment of indolent cancers 
that eventually affects man’s quality of life and can also put the cost-effectiveness 
in question. However, RCTs in general lack long follow-up and alternative strategies 
in order to find a better harm-benefit balance that could make PSA screening more 
effective. Therefore, modeling is probably the only way through which we can find 
an optimum screening strategy among various competing screening protocols.
In 2018 the USPSTF issued a C-recommendation on screening for prostate cancer for 
men aged 55-69, urging clinicians to inform men about the potential benefits and 
harms of prostate-specific antigen (PSA) screening for prostate cancer3. The benefits 
are prostate cancer deaths prevented, life-years gained and prevention of advanced 
disease, and the harms overdiagnosis, living with a cancer diagnosis, and severe 
complications of treatment. The USPSTF indicated, based on the ERSPC data, that 
screening may avert 1 to 2 prostate cancer deaths over 13 years follow-up per 1000 
men screened, and estimated a 20% to 50% risk of overdiagnosis. We agree that 
the balance between benefits and harms of PSA testing is too delicate to support 
screening men over the entire age range 55-69. But this not because PSA testing is 
not effective. A modeling study including quality of life estimates showed that it is 
better not to screen above age 634. In chapter 2, using the same model, we indicated 
that the ratio between benefits and harms is much better for men screened at ages 
55-63 than the broader 55-69 age group. This indicates that there would be an op-
portunity for USPSTF to give a B recommendation for prostate cancer screening for 
the narrower age group, 55-63 years. Pashayan etal5 indicated that the probability of 
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overdiagnosis increased with age, being highest for the age group 65-69. This report 
is in agreement with our findings in chapter 2 and chapter 3.
Furthermore, modeling plays a crucial role when a trial fails to shows a statistically 
significant cancer mortality benefit. For instance the PLCO trial didn’t show a pros-
tate cancer mortality benefit for PSA screening, unlike the ERSPC trial2,6. However, 
a secondary model based analysis showed that after accounting for differences in 
implementation and settings between the two trials, the ERSPC and PLCO provide 
compatible evidence that screening reduces prostate cancer mortality7. Similarly CAP 
is the 2nd of the two trials that are clearly underpowered for statistical significance8. 
In chapter 2 of this thesis, after replicating the trial with our micro-simulation 
model, we indicated that the insignificant results from the CAP trial, the trial with 
a single PSA test and low acceptance rate (36%), could not refute PSA screening to be 
effective. The statistical insignificant result from the CAP trial should be interpreted 
by taking into consideration the low acceptance rate and the single test applied only 
at age 50. To see the beneficial effects of PSA screening, factors like sufficient at-
tendance rate and repeated testing (apart from contamination of the control group 
as seen in the PLCO trial) are very crucial. The French center, one of the centers in 
the ERSPC trial, was not included in the mortality analyses since acceptance rates 
below 45% were expected to dilute the power of the trial9. Therefore the results in 
chapter 2 implies that, even when a trial shows no mortality benefit, well-validated 
modelling can strengthen the evidence on targeted interventions for improved early 
detection. Although a more detailed analysis with individual data from the CAP-trial 
may inform the models better, we feel it is imperative to show these results now for 
future health policy making.
To implement prostate cancer screening at a population level, a cost-effectiveness 
analysis is one of the key points policy-makers need to consider. In chapter 3, we 
assessed the harms, benefits, and cost-effectiveness of more than 200 screening 
scenarios. In this study, we also included the effect of PSA screening in the age group 
50 to 55, where limited information is available, unlike several cost-effectiveness 
studies that start screening from age fifty five1,4,10,11. However, our cost-effectiveness 
analysis doesn’t support screening for prostate cancer before age 55. Similarly, 
screening beyond age 64 is not the preferred strategy according to the analysis. Us-
ing the commonly used WTP of €20,000, we found that triennial screening between 
age 55 to 64 would be the optimal screening strategy. At what age screening should 
start, at what age it should stop, and what screening interval should be used has 
been some of the debatable questions in prostate cancer screening, and in this chap-
ter, we tried to answer these important questions. However, these results should be 
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interpreted carefully as they are projected for a population with average health risk. 
This means that the results may not be applicable under certain clinical conditions, 
such as a man with high risks of prostate cancer (for instance with a first degree 
family history) may benefit from starting screening at an earlier age or extending 
the screening stop age that was recommended in the study. Additionally, the use of 
triage tests like mpMRI (chapter 4 and 5) and considering comorbidity status could 
further reduce the risk of overdiagnosis and/or improve the cost-effectiveness12-18.
Reducing the harms of PSA screening using MRI
Nowadays, mpMRI is increasingly used to select men before biopsy and to perform 
targeted biopsy for suspicious lesions on MRI. Studies show that the use of mpMRI 
before biopsy and MRI-targeted biopsy is superior to the standard TRUSGB, by detect-
ing less clinically insignificant cancers, and more clinical significant cancers12,13,19. 
However, quantifying the actual effects of MRI on overdiagnosis or cancer related 
mortality requires much longer follow-up time than the existing MRI trials and 
therefore to be modeled.
In chapter 3, after comparing more than 200 screening strategies, we found that 
PSA based screening would be optimal when we screen between age 55 to 64 at 
three-year intervals. Although this age targeted screening relatively reduces the risk 
of overdiagnosis, the strategy  was still associated with about 36% of overdiagnosis 
(out of screen detected), and there could be a room to further reduce this risk of 
overdiagnosis. In chapter 4 we incorporated mpMRI as a triage test before biopsy 
and an MRI-guided biopsy was used instead of the TRUSGB. Our main results show 
that the screening protocol that includes MRI substantially reduces overdiagnosis 
(-43%) and biopsy procedures (-30%) and resulted in a better harm-benefit ratio 
compared to the protocol without MRI. A better approach to improve the harm-
benefit ratio of PSA based prostate cancer screening would be to drastically reduce 
the harm, preferably while improving or maintaining the currently established 
benefits20. Interestingly, our findings are also in line with this concept in which the 
cancer mortality reduction, LYs, and QALYs gained are slightly increased in the MRI 
pathway than the regular PSA based screening pathway apart from the substantial 
reductions in overdiagnosis.
Despite the advantages, still there is a reluctance to include MRI into practice 
guidelines because it is perceived to be an expensive method21. It remains uncertain 
whether it is cost-effective, especially in a population-based screening setting. In 
chapter 5, we estimated the cost-effectiveness of the MRI screening pathway com-
pared to the regular pathway, using the same screening strategies used in chapter 
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3. Our results show that the MRI strategy is more cost-effective (in about 84% of the 
probabilistic sensitivity analyses) than the regular screening strategy, at a WTP of 
€20,000. These findings together with the results in chapter 4 show that incorpora-
tion of mpMRI after a positive PSA test result followed by MRIGB is a promising 
method in addition to age targeted screening (chapter 3), and this can inform policy 
makers better regarding future implementation of prostate cancer screening at a 
population level.
There are some limitations associated with the findings in Chapter 4 and 5. First, 
we did not consider the combined approach of TRUGB and MRIGB. Studies show 
that the MRIGB still misses 10-20% of the clinically significant cancers12,19,22 and also 
has more miss-classification of grades than the combined biopsy23. Second, the per-
formance of MRIGB may vary in biopsy naïve and previously biopsied men, which 
has not explicitly been modeled in our studies. But in general, studies show that 
the performance of MRIGB is superior to that of TRUSGB either in biopsy naïve or 
previously biopsied men (although the degree may vary)13,24. The interpretation of 
our cost-effectiveness results in chapter 5 also needs caution since the costs of MRI 
are much lower in Europe than in countries like the United States.
Opportunistic PSA testing
In general, it is clear that opportunistic PSA testing, currently conducted widely, 
is less effective for reducing prostate cancer related mortality and associated with 
a higher risk of overdiagnosis as compared to organized population screening. 
For instance, the Goteborg trial showed that opportunistic screening resulted in 
a 12% relative prostate cancer mortality reduction as compared to 42% for orga-
nized screening25. The corresponding numbers of men needed to be diagnosed to 
avoid one prostate cancer death were 23 vs. 13. Screening at older age is among 
several reasons that makes opportunistic screening ineffective. For example, in the 
Netherlands, half of men who receive an initial PSA test is 70 years or older, of 
whom half are aged ≥80 years26,27. Therefore, from chapter 2 through chapter 5, we 
have tried to indicate possible future directions to implement organized population 
based prostate cancer screening and also showed how modelling is crucial in policy 
decision process. However, existing guidelines on prostate cancer screening recom-
mend individual PSA testing and the decision to undergo the test should be shared 
between patients and their physicians3,28. But given the natural history of prostate 
cancer, it is usually challenging to give comprehensive and balanced information 
about prostate cancer screening. Web-based tools can be used to inform/support 
patient-physician decision about prostate cancer screening.
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Web based tool to support patient physician decision about 
prostate cancer screening
Chapter 6 describes the calculator that we have developed. This calculator was 
designed for asymptomatic men between ages 50 and 70, and it has three distinct 
parts. This enables patients and their physicians to use the calculator at three key 
decision points: the decision to take a PSA test, the decision to go for a biopsy, 
and the decision to select a treatment for localized prostate cancer (radical pros-
tatectomy or radiation therapy). Such predictive information of the calculator at 
different decision points has considerable value and can provide benefits for the 
men and physicians by reducing unnecessary worry from the PSA test, unnecessary 
biopsy, overdiagnosis and moreover unnecessary treatment.
The main strength of the calculator is that we were able of incorporating the lifetime 
risk of dying from prostate cancer, the risk of overdiagnosis, and possible life-years 
gained from a specific treatment. Although previous online prostate cancer calcula-
tors29-32 have their own strength (like having more predictors), none of them were 
able to account these long-term effects of PSA screening, mainly due to the existing 
trial data, on which the calculators depend on, are not long enough to observe the 
long term effects of PSA screening.
A main limitation in this study is that the calculator misses certain factors such 
as family history, previous biopsy history, prostate volume, PSA velocity, race, and 
comorbidity status. This makes the calculator mainly applicable to men with an 
average risk of prostate cancer, and doesn’t apply to men with additional risks. 
Furthermore, no specific decision threshold is provided in the calculator, so the 
final decision to proceed with a PSA test or biopsy or treatment is still left with the 
patient and physician based on the risk of having the cancer, risk of dying from the 
cancer, and the long-term harms and benefits of the test provided in the calculator.
7.3 FURTHER RESEARCH DIRECTIONS
Stratifying with comorbidity status and PSA level
As already mentioned elsewhere in this thesis, comorbidity status is not included 
in our studies. However, it may be important to account for the comorbidity status 
when analyzing an optimal screening strategy. This is because PSA screening in men 
with more comorbidity is associated with high risks of overdiagnosis and subsequent 
overtreatment as these men are more likely to die from other competing diseases/
conditions than prostate cancer. Although a previous study indicated the effect of 
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comorbidity on the age of screening cessation, the study had major limitations: the 
comorbidity lifetable used only starts at age 65, and are also not relative to a spe-
cific disease but to comorbidity scores33. Stratifying by PSA level is another method 
that can reduce unnecessary test and overdiagnosis. Heijnsdijk et al, reported that 
compared to biennial screening, PSA stratified screening strategy substantially 
reduce number of tests and modestly reduce overdiagnosis34. However, this study 
also assumed that 100% of men received biopsy after a positive PSA test regardless 
of patients comorbidity status, and this could be one reason why the overdiagnosis 
only reduced modestly. Therefore, more research need to be conducted about the 
effect of stratifying both by comorbidity and PSA level on the harm-benefit balance 
of PSA screening.
Combined biopsy (MRI-targeted and Systematic biopsy)
Our studies, in chapter 4 and 5, assess the effects of MRI-targeted biopsy and system-
atic biopsy separately. However, combined biopsy could result in better detection 
of clinically significant cancer and has a lower misclassification rate of grade than 
using either TRUSGB or MRIGB alone23. On the other hand, it is also important to 
know that combined biopsy also increases the detection of clinically insignificant 
cancer23,27. Hence future research should analyze the effects of using combined 
biopsy, especially in a population based screening setting. Furthermore, there are 
various ways to use MRI in a screening setting, and it is not clear which one is best. 
For instance, if an mpMRI does not detect lesions suspicious for prostate cancer, 
either no biopsy or a standard biopsy can be performed. However, in our studies 
(chapter 4 and 5) only the no biopsy option was considered, and this caused missing 
of 11% clinically significant cancer (due to not performing biopsy) as also reported 
in Pokorny et al14. Another point is that we evaluated the effects of MRI only in a 
single screening strategy (an optimal screening strategy that we found in chapter 3).
Novel molecular tests
Considering novel tests that use biomarkers and genetic polymorphism can result 
in a better detection of men with clinically significant cancer and also facilitate 
therapeutic decision. Various novel molecular tests, such as single nucleotide 
polymorphisms, 4Kscore, PCA3, SelecMDx, and Prostate Health Index, have been 
proposed to improve the selection of men with clinically significant prostate cancer, 
reduce unnecessary biopsies and reduce detection of clinically insignificant cancer35 
36. The aim of using these tests is not to replace the PSA test, but rather to provide 
complimentary information that can enhance the prediction of high grade cancer. 
When these novel tests are used together with other diagnostic tools such as mpMRI, 
they might also reduce unnecessary biopsies without or with minimal risks of miss-
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ing clinically significant cancers37,38. For instance, in chapter 4 we indicated that the 
use of mpMRI as a reflex test misses to detect 11% of clinically significant cancer, 
and integrating such novel tests would reduce this risk of missing clinically relevant 
cancers. Future research should analyze the exact effects of using such novel mo-
lecular tests in the harm-benefit balance of prostate cancer screening under various 
screening scenarios.
7.4 MAIN CONCLUSIONS
The following conclusions are made, based on the results of this thesis:
• Modeling can play an important role in policy decisions for (prostate) cancer con-
trol. This is especially true when it is difficult to get sufficient information, such 
as long-term effects of a given intervention, from RCTs and other observational 
studies.
• Compared to the wide 55-69 age range for PSA testing used in the USPSTF’s latest 
“C” recommendation for PSA testing, the 55-63 age range has a better harm-
benefit balance
• The result reported from the CAP trial about the insignificant prostate cancer 
mortality benefit of one PSA screening test (at 36% coverage) cannot refute PSA 
screening to be effective. The CAP trial rather should be interpreted taking into 
account the single test offered and its low acceptance rate (36%).
• The optimal age targeted PSA based prostate cancer screening would be screening 
between age 55-64 at three year intervals. Screening above this age is associated 
with high risks of overdiagnosis and higher costs. Similarly screening before age 
55 is not supported based on the cost-effectiveness analysis.
• Using mpMRI as a triage test after a positive PSA test result followed by an MR-
guided biopsy can substantially reduce the risk of overdiagnosis and improve the 
harm-benefit ratio as compared to the regular PSA screening. This method also 
significantly reduces the need for biopsy (up to 30%).
• Incorporation of mpMRI in prostate cancer screening with subsequent MRI 
guided biopsy has also a high probability to be cost-effective compared to the 
regular PSA screening.
• We developed a prostate cancer risk calculator that incorporates both the long 
term harms and benefits of a PSA testing. The calculator can assist patients and 
their physicians before deciding to undergo a PSA test, a biopsy, and select the 
treatment. Together with other risk calculators, it could improve the shared deci-




• The USPSTF has still room to revise its C recommendation for PSA based prostate 
cancer screening. More specifically, there may be a case for the USPSTF to con-
sider a B-recommendation for PSA testing for the 55–63 age group.
• The implementation of organized population based prostate cancer screening 
should be considered by policy makers taking into account the current evidence 
on prostate cancer screening, including modeling studies, being a cost-effective 
public health intervention.
• mpMRI and subsequent targeted biopsy should be considered in the implementa-
tion of prostate cancer screening at a population level because this method sub-
stantially reduces overdiagnosis which is one of the main barriers that hinders 
the introduction of population-based PSA screening.
• More risk stratification like screening by comorbidity status, and using of novel 
molecular tests could also be considered to make PSA screening more effective 
by further reducing the risk of overdiagnosis and unnecessary biopsy.
• Use a web-based tool with long-term harms and benefits, like the one included in 
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Prostate cancer is the second most commonly diagnosed cancer and the 5th leading 
cause of cancer mortality in men across the world. In Europe the disease has become 
the second frequent cause of cancer-related death in men behind lung cancer.
The ERSPC, PLCO and CAP trials were the three largest randomized controlled trials 
that assessed the effect of PSA screening on prostate cancer mortality reduction. 
Although the PLCO and CAP trials did not show a significant mortality benefit 
for PSA screening, the ERSPC trial showed after 16 years follow-up a 20% relative 
prostate cancer mortality reduction for the intervention (screening) arm. There are 
various differences in the design and implementation among the trials that could 
explain the discrepancy. A secondary model based analysis showed that after ac-
counting for the differences in implementation and settings between the ERSPC and 
PLCO, the two trials provide compatible evidence that screening reduces prostate 
cancer. Whether the insignificant results from the CAP trial change the evidence of 
PSA testing was addressed in this thesis (Chapter 2) by replicating the trial using a 
simulation model.
Despite prostate cancer remains among the most common causes of cancer-related 
morbidity and mortality among men, and various studies showed the benefit of 
PSA screening on prostate cancer mortality reduction, a population-based prostate 
cancer screening program has not yet been introduced in almost all countries, in 
contrast with breast, cervical, and colorectal cancers. Important questions, like at 
what age PSA screening should start, at what age it should stop, and at what interval 
to screen should be used, remain debatable and need to be explored more. Answer-
ing these questions needs comparisons of various alternative screening strategies/
scenarios as well as a long follow-up time, which are unlikely or even impossible 
from trial studies. Similarly, assessing the effects of promising triage tests like MRI 
on the reduction of the risk of overdiagnosis needs long-term follow-up due to the 
long lead time of prostate cancer. To answer these questions modeling can play 
crucial roles, which can help to assess the harms, benefits, and cost-effectiveness of 
different alternative prostate cancer screening strategies.
Throughout this thesis, the MIcro Simulation SCreening ANalysis (MISCAN) model 
for prostate cancer was used to assess the effects of prostate cancer screening, 
particularly at a population level. The first part of this thesis describes how model-
ing can play a crucial role in policy decision making process regarding (prostate) 
cancer screening. Furthermore, we assessed an optimal prostate cancer screening 
strategy at a population level by comparing several alternative screening strategies. 
The second part of this thesis evaluates the effects of using MRI in prostate cancer 
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screening and its cost effectiveness in a population screening setting. The third part 
of the thesis describes the calculator that includes long-term harms and benefits of 
PSA-based prostate cancer screening.
Chapter 2 indicates how modeling can provide additional information about PSA 
screening beyond the observed data of randomized controlled trials. In 2018 the 
USPSTF gave a “C”  recommendation for prostate cancer screening between the age 
55 to 69, mainly based on the ERSPC trial. However, given the natural history of 
prostate cancer with on average slow progression, predicting the harm- benefit ratio 
based on trial data with a relatively short follow-up period is difficult. Using the MIS-
CAN prostate cancer model we showed that the harm-benefit ratio (overdiagnosis/
death averted) of PSA screening between the age 55-63 is much better than the 55-69 
age group (3.2 vs 5.4), and therefore the USPSTF could consider a B recommendation. 
Apart from this, in chapter 2 using the MISCAN prostate model, we indicated that 
the insignificant results from the CAP trial do not refute the existing evidence about 
the mortality benefit of PSA screening, rather the results should be interpreted tak-
ing into consideration the single test offered at age 50 and its low acceptance rate 
(36%).
In chapter 3, using the MISCAN prostate model, we evaluated more than 200 differ-
ent PSA screening strategies by considering different starting ages, stopping ages, 
and intervals of screening. Using a willingness-to-pay threshold of €20,000 per QALY 
gained, we found that screening between the age 55 to 64 at three years intervals 
would be the optimal population-based screening strategy. This strategy resulted in 
a 27% prostate cancer mortality reduction, 28 life- years gained per 1000 men, and a 
36% risk of overdiagnosis.
The aim of chapter 4 was to determine the effects of using mpMRI and MRI-guided 
biopsy on prostate cancer screening. mpMRI has become an important test to select 
men with a positive PSA test result before biopsy and perform targeted biopsy. Using 
the MISCAN prostate model, we added mpMRI to the optimal screening strategy that 
we found in chapter 3 and replaced the regular systematic biopsy with MRI-guided 
biopsy. Based on this, we found that when mpMRI is used after a positive PSA test 
result and followed by an MRI-guided biopsy, it resulted in a substantial reduction of 
biopsies and risk of overdiagnosis, and a better harm-benefit balance (overdiagnosis 
per death averted) compared to the regular PSA screening (all positive PSA test are 
followed by systematic biopsy).
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In chapter 5, it was assessed whether the MRI based prostate cancer screening 
strategy is more cost-effective than the regular PSA-based screening using the same 
model as used in chapter 4. We found that in 84% of the probabilistic sensitivity 
analyses, the MRI-based screening strategy is more cost-effective than the regular 
screening pathway.
From chapter 2 through chapter 5, we tried to show possible directions that can 
help future implementation of  prostate cancer screening at a population level. The 
present guidelines, however, recommend individual PSA screening and the decision 
to undergo the test should be shared between patients and their physician. There-
fore, in chapter 6, we developed a calculator aiming to improve patient-physician 
decision before taking a PSA test, before undergoing biopsy, and before deciding to 
treat or not. The risk of having (high grade) prostate cancer, prostate cancer related 
death, overdiagnosis, and expected life-years gained substantially varied across the 
different predictors included in the model.
Conclusions and recommendations
Based on the results of this thesis the following conclusions are derived:
• Modeling can play an important role in policy decisions for (prostate) cancer con-
trol. This is especially true when it is difficult to get sufficient information, such 
as long-term effects of a given intervention, from RCTs and other observational 
studies.
• Compared to the wide 55-69 age range for PSA testing used in the USPSTF’s latest 
“C ” recommendation for PSA testing, the 55-63 age range (simulated in our 
model) has a better harm-benefit balance.
• The insignificant result reported from the CAP trial about the mortality benefit 
of PSA screening cannot refute PSA screening to be effective. The CAP trial rather 
should be interpreted taking into account the single test offered and its low 
acceptance rate (36%).
• The optimal age targeted PSA based prostate cancer screening would be screening 
between age 55-64 at three year intervals. Screening above this age is associated 
with high risks of overdiagnosis and higher costs. Similarly screening before age 
55 is not supported based on the cost-effectiveness analysis.
• Using mpMRI as a triage test after a positive PSA test result followed by an MR-
guided biopsy can substantially reduce the risk of overdiagnosis and improve the 
harm-benefit ratio as compared to the regular PSA screening. This method also 
significantly reduce the need for biopsy (up to 30%).
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• Incorporation of mpMRI in prostate cancer screening with subsequent MRI 
guided biopsy has also a high probability to be cost-effective compared to the 
regular PSA screening.
• We developed a prostate cancer risk calculator that incorporates both the long 
term harms and benefits of a PSA testing. The calculator can assists patients 
and their physicians before deciding to undergo a PSA test, a biopsy, and select 
the treatment. Together with other risk calculators, it could improve the shared 
decision between patients and physicians.
Based on the results and conclusions of this thesis, the following recommendations 
are given:
• The USPSTF has still room to revise its C recommendation for PSA based prostate 
cancer screening. More specifically, there may be a case for the USPSTF to con-
sider a B-recommendation for PSA testing for the 55–63 age group.
• The implementation of organized population based prostate cancer screening 
should be considered by policy makers taking into account the current evidence 
on prostate cancer screening, including modeling studies.
• mpMRI and subsequent targeted biopsy should be considered in the implementa-
tion of prostate cancer screening at a population level because this method sub-
stantially reduces overdiagnosis which is one of the main barriers that hinders 
the introduction of population-based PSA screening.
• More risk stratification like screening by comorbidity status, and using of novel 
molecular tests could also be considered to make PSA screening more effective 
by further reducing the risk of overdiagnosis and unnecessary biopsy.
• Build a web based tool with long term harms sand benefit, like the one included 







Prostaatkanker is de op een na meest gediagnosticeerde kanker en de 5e oorzaak van 
kankersterfte bij mannen wereldwijd. In Europa is de ziekte de tweede doodsoor-
zaak bij mannen na longkanker.
De ERSPC-, PLCO- en CAP-trials waren de drie grote gerandomiseerde gecontroleerde 
onderzoeken die het effect van PSA-screening op de vermindering van de sterfte 
aan prostaatkanker evalueerden. Hoewel de PLCO- en CAP-onderzoeken geen sig-
nificante mortaliteitsreductie lieten zien voor PSA-screening, toonde de ERSPC-stu-
die na 16 jaar follow-up een relatieve reductie van de prostaatkankersterfte met 
20% voor de interventie (screening) -arm. Er zijn een aantal verschillen in opzet 
en uitvoering tussen de trials die de discrepantie zouden kunnen verklaren. Een 
secundaire modelgebaseerde analyse toonde aan dat, als rekening gehouden wordt 
met de  verschillen in opzet en uitvoering tussen de ERSPC en PLCO, de twee trials 
vergelijkbaar compatibel bewijs leveren dat screening de sterfte aan prostaatkanker 
vermindert. Of de niet-significante resultaten van de CAP-trial het bewijs van PSA 
screening veranderen, werd in dit proefschrift (Hoofdstuk 2) onderzocht door de 
studie te repliceren met behulp van een simulatiemodel.
Ondanks dat prostaatkanker nog steeds de meest voorkomende oorzaak is van 
kankergerelateerde morbiditeit en mortaliteit bij mannen, en verschillende studies 
het effect van PSA-screening op de vermindering van de sterfte aan prostaatkanker 
hebben aangetoond, is in bijna geen enkel land een bevolkingsonderzoek naar 
prostaatkanker geïntroduceerd in tegenstelling tot borst-, baarmoederhals- en 
colorectale kanker. Belangrijke vragen, zoals de leeftijd waarop PSA-screening zou 
moeten beginnen, op welke leeftijd het zou moeten stoppen en met welk interval er 
gescreend moet worden, blijven discutabel en moeten verder worden onderzocht. 
Om deze vragen te beantwoorden, zijn vergelijkingen nodig van verschillende 
alternatieve screeningsstrategieën / -scenario’s, evenals een lange follow-uptijd die 
onwaarschijnlijk of zelfs onmogelijk is uit trials. Evenzo vereist het beoordelen van 
de effecten van veelbelovende triagetests, zoals MRI, op de vermindering van het 
risico op overdiagnose een langdurige follow-up vanwege het langzame verloop 
van prostaatkanker. Hier speelt modellering een cruciale rol, wat kan helpen bij 
het beoordelen van de nadelen, voordelen en kosteneffectiviteit van verschillende 
alternatieve screeningsstrategieën voor prostaatkanker.
In dit proefschrift werd het MIcro Simulation SCreening ANalysis (MISCAN) -mo-
del voor prostaatkanker gebruikt om de effecten van prostaatkankerscreening te 
beoordelen, met name op populatieniveau. Het eerste deel van dit proefschrift 
beschrijft hoe modellering een cruciale rol kan spelen in het besluitvormingsproces 
Samenvatting
158
van beleid met betrekking tot (prostaat) kankerscreening. Verder hebben we een 
optimale screeningstrategie voor prostaatkanker op populatieniveau beoordeeld 
door verschillende alternatieve screeningstrategieën te vergelijken. Het tweede deel 
van dit proefschrift evalueert de effecten van het gebruik van MRI bij screening 
op prostaatkanker en de kosteneffectiviteit ervan in een bevolkingsonderzoek. Het 
derde deel van het proefschrift beschrijft een calculator die de langetermijn nadelen 
en voordelen van prostaatkankerscreening met PSA omvat.
Hoofdstuk 2 gaf aan hoe modellering aanvullende informatie kan opleveren over 
PSA-screening bovenopde geobserveerde gegevens van gerandomiseerde gecontro-
leerde studies. In 2018 gaf de USPSTF een “C” -aanbeveling voor prostaatkankerscree-
ning tussen de 55 en 69 jaar, voornamelijk gebaseerd op de ERSPC-studie. Gezien de 
natuurlijk beloopvan prostaatkanker, met een langzame groei, is het echter moei-
lijk om de balans tussen nadelen en voordelen op basis van onderzoeksgegevens te 
voorspellen. Daarom hebben we met behulp van het MISCAN-prostaatkankermodel 
aangetoond dat de nadelen-voordelenverhouding (overdiagnose / vermeden dood) 
van PSA-screening tussen de 55-63 jaar veel beter is dan die van de leeftijdsgroep 55-
69 (3,2 versus 5,4). en de USPSTF zou hiervoor dus een B-aanbeveling kunnen over-
wegen. Afgezien hiervan hebben we in hoofdstuk 2 met behulp van het MISCAN-
-prostaatmodel aangegeven dat de niet significante resultaten van de CAP-studie het 
bestaande bewijs over de mortaliteitsreductie van PSA-screening niet weerleggen, 
maar dat de resultaten moeten worden geïnterpreteerd rekening houdend met de 
enkele test, aangeboden op de leeftijd van 50, en het lage opkomstpercentage (36%).
In hoofdstuk 3 hebben we met behulp van het MISCAN prostaatmodel meer dan 
200 verschillende PSA-screeningsstrategieën met verschillende startleeftijden, 
stopleeftijden en intervallen van screening geëvalueerd. Met behulp van een WTP-
-drempel van € 20.000 per gewonnen QALY, ontdekten we dat screening tussen de 
55 en 64 jaar met een interval van drie jaar de optimale screeningstrategie voor een 
bevolkingsonderzoek zou zijn. Deze strategie resulteerde in een reductie van 27% 
van de prostaatkankersterfte en 28 gewonnen levensjaren per 1000 mannen, en een 
risico op overdiagnose van 36%.
Het doel van hoofdstuk 4 was om de effecten te bepalen van het gebruik van mp-
MRI en MRI-geleide biopsie op prostaatkankerscreening. mpMRI is een belangrijke 
test geworden om mannente selecteren met een positief PSA-testresultaat vóór een 
biopsie, om een gerichte biopsie uit te voeren. Met behulp van het MISCAN-pros-
taatmodel hebben we mpMRI toegevoegd aan de optimale screeningstrategie die we 
in hoofdstuk 3 hebben gevonden en hebben we de reguliere systematische biopsie 
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vervangen door MRI-geleide biopsie. Op basis hiervan ontdekten we dat wanneer 
mpMRI wordt gebruikt na een positief PSA-testresultaat gevolgd door een MRI-ge-
leide biopsie, dit resulteerde in een substantiële vermindering van biopsieën en het 
risico op overdiagnose, en een betere nadelen-voordelenverhouding (over diagnose 
per vermeden dood) vergeleken met de reguliere PSA-screening (alle mannen met 
een positieve PSA-test  krijgen een systematische biopsie).
In hoofdstuk 5 werd onderzocht of de MRI-gebaseerde prostaatkankerscreenings-
strategie kosteneffectiever is dan de reguliere PSA-gebaseerde screening met het-
zelfde model als in hoofdstuk 4. We vonden dat in 84% van de probabilistische 
gevoeligheidsanalyses de MRI -gebaseerde screeningsstrategie kosteneffectiever is 
dan het reguliere screeningstraject.
Van hoofdstuk 2 tot en met hoofdstuk 5 hebben we geprobeerd mogelijke rich-
tingen te laten zien die kunnen helpen bij de toekomstige implementatie van 
prostaatkankerscreening op populatieniveau. De huidige richtlijnen bevelen echter 
individuele PSA-screening aan en de beslissing om de test te ondergaan moet worden 
genomen door patiënten en hun arts samen. Daarom hebben we in Hoofdstuk 6 een 
calculator ontwikkeld om de beslissing van de patiënt en arts te verbeteren voordat 
een PSA-test wordt gedaan, voordat een biopsie wordt ondergaan en voordat wordt 
besloten om al dan niet te behandelen. Het risico op (hooggradige) prostaatkanker, 
aan prostaatkanker gerelateerde sterfte, overdiagnose en verwachte gewonnen le-
vensjaren varieerde aanzienlijk tussen de verschillende parameters die in het model 
zijn opgenomen.
Conclusies en Aanbevelingen
Op basis van de resultaten van dit proefschrift worden de volgende conclusies ge-
trokken:
• Modellering kan een belangrijke rol spelen bij beleidsbeslissingen over scree-
ning en behandeling van (prostaat) kanker. Dit geldt vooral als het moeilijk is om 
voldoende informatie, zoals langetermijneffecten van een interventie, uit RCT's 
en andere observationele studies te halen.
• Vergeleken met de brede leeftijdsrange van 55-69 jaar voor PSA-testen die wordt 
gebruikt in de nieuwste "C" -aanbeveling van de USPSTF voor PSA-screening, 
geeft de leeftijdsrange van 55-63 jaar (gesimuleerd in ons model) een betere 
balans tussen voor- en nadelen.
• Het niet-significante resultaat van de CAP-studie over de mortaliteitsreductie van 
PSA-screening kan niet weerleggen dat PSA-screening effectief is. De CAP-studie 
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moet veeleer worden geïnterpreteerd als  het aanbieden van één test en het lage 
acceptatiepercentage (36%).
• Prostaatkanker screening tussen leeftijd 55-64 jaar met intervallen van drie jaar 
is optimaal. Screening boven deze leeftijd gaat gepaard met een hoog risico op 
overdiagnose en hogere kosten. Evenzo wordt screening onder de leeftijd van 55 
jaar niet ondersteund op basis van de kosteneffectiviteitsanalyse.
• Het gebruik van mpMRI als triagetest na een positief PSA-testresultaat gevolgd 
door een MR-geleide biopsie kan het risico op overdiagnose aanzienlijk vermin-
deren en de balans tussen voor- en nadelen verbeteren in vergelijking met de 
reguliere PSA-screening. Deze methode vermindert ook aanzienlijk de behoefte 
aan biopsie (tot 30%).
• Het uitvoeren van mpMRI in prostaatkankerscreening met daaropvolgende 
MRI-geleide biopsie is waarschijnlijk ook kosteneffectief in vergelijking met de 
reguliere PSA-screening.
• We hebben een risicocalculator voor prostaatkanker ontwikkeld die zowel 
de lange-termijn nadelen en voordelen van een PSA-test omvat. De calculator 
kan patiënten en hun artsen helpen alvorens te beslissen om een  PSA-test of 
een biopsie te ondergaan en een behandeling te selecteren. Samen met andere 
risicocalculatoren zou dit de gezamelijke beslissing tussen patiënten en artsen 
kunnen verbeteren.
Op basis van de resultaten en conclusies van dit proefschrift worden de volgende 
aanbevelingen gedaan:
• De USPSTF heeft nog ruimte om haar C-aanbeveling voor op PSA-screening op 
prostaatkanker te herzien in een  B-aanbeveling voor PSA-screening voor de 
leeftijdsgroep 55-63.
• De implementatie van een georganiseerd  bevolkingsonderzoek voor prostaat-
kanker zou door beleidsmakers moeten worden overwogen, rekening houdend 
met de huidige data over screening op prostaatkanker, met inbegrip van model-
studies.
• mpMRI en daaropvolgende gerichte biopsie moeten worden overwogen bij de 
implementatie van prostaatkankerscreening op populatieniveau, omdat deze 
methode overdiagnose substantieel vermindert, wat het belangrijkste probleem 
is dat de introductie van prostaatkankerscreening belemmert.
• Meer risicostratificatie, zoals screening afhankelijk van co-morbiditeit en het 
gebruik van nieuwe moleculaire tests, moet ook worden overwogen om PSA-
-screening effectiever te maken door het risico op overdiagnose en onnodige 
biopsie verder te verminderen.
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• Een internet tool met voordelen en nadelen op lange termijn, zoals de tool die 
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